| Excerpt | Reference |
|---|
| "Rheumatoid arthritis is a multisystem disease, with many clinical forms bearing close resemblance to systemic lupus erythematosus, dermatomyositis or polyarteritis nodosa." | ( Stern, WK, 1979) |
| "Treatment of rheumatoid arthritis is often frustrating for patient and physician alike because of its chronic nature and our lack of knowledge about precise cause." | ( Kaye, RL; Pemberton, RE, 1976) |
| "Rheumatoid arthritis is associated with abnormalities in macrophage, lymphocyte, and fibroblast functions." | ( Boyce, E, 1992) |
| "Rheumatoid arthritis is a chronic inflammatory disorder with considerable evidence of impaired regulation of the immune response, including defective suppressor cell function, especially in the synovial membrane." | ( Brown-Galatola, CH; Hall, ND, 1992) |
| "Rheumatoid arthritis is a complex inflammatory disease of unknown cause." | ( Beckham, JC; Caldwell, DS; Currie, MS; Keefe, FJ; Peterson, BL; Pippen, AM; Weinberg, JB, 1992) |
| "Rheumatoid arthritis is a chronic polyarthritis in which active inflamed joints coexist with joints in remission." | ( Berná, L; Carrió, I; Diez, C; Estorch, M; Martínez-Duncker, D; Torres, G, 1992) |
| "Rheumatoid arthritis is a systemic disease." | ( Takagishi, K; Yamamoto, M, 1992) |
| "Rheumatoid arthritis is a severe disease and it is difficult to prevent the progression of disease." | ( Inoue, T; Miyamoto, S, 1992) |
| "Rheumatoid arthritis is a chronic inflammatory disease that results in progressive disability and increased mortality." | ( Murphy, NG; Zurier, RB, 1991) |
| "Rheumatoid arthritis is characterized by chronic inflammation and proliferation of a number of important elements within the joint including the synovial fibroblasts." | ( Breit, SN; Penny, R; Por, SB; Richter, M; Shelley, L; Thornton, SC, 1991) |
| "Osteoporosis in rheumatoid arthritis is observed even in non-corticosteroid treated patients; articular lesions with subsequent reduction in physical activity appear to play an important role in axial bone loss in rheumatoid arthritis." | ( Altomonte, L; Magaro, M; Mirone, L; Piane, D; Serra, F; Tricerri, A; Zoli, A, 1991) |
| "Rheumatoid arthritis is being increasingly treated with sulphasalazine." | ( Boyd, O; Gibbs, AR; Smith, AP, 1990) |
| "Rheumatoid arthritis is a systemic disorder, but primarily involves chronic polyarticular inflammation." | ( Sterling, LP, 1990) |
| "Rheumatoid arthritis is a destructive systemic disorder characterized by remissions and exacerbations." | ( Abedi, E; Dockery, KM; Sismanis, A, 1991) |
| "Rheumatoid arthritis is not considered to be associated with recurrent thrombosis." | ( Smith, RE; Theisen, AL, 1990) |
| "The treatment of rheumatoid arthritis is undergoing steady change as new medications are approved and new regimens are attempted." | ( Furst, DE, 1990) |
| "Rheumatoid arthritis is a disorder that frequently can be controlled with a program of physical therapy, rest and therapeutic doses of aspirin or another nonsteroidal anti-inflammatory medication." | ( Clegg, DO; Ward, JR, 1987) |
| "Rheumatoid arthritis is characterized by increased activity of macrophages which produce toxic forms of oxygen." | ( Aaseth, J; Jellum, E; Munthe, E, 1986) |
| "Rheumatoid arthritis is a chronic lifelong disease, facts which must be considered when concepts of therapy are developed." | ( Hohmeister, R, 1988) |
| "Rheumatoid arthritis is a disorder characterized by chronic inflammation affecting predominantly articular tissues, leading in some instances to disruption of the normal structure and function of the joint." | ( Krane, SM; Simon, LS, 1986) |
| "Rheumatoid arthritis is a chronic, systemic inflammatory disease, characterized by polyarticular inflammation, joint destruction, deformity and loss of function." | ( Christman, C, 1987) |
| "Early rheumatoid arthritis is a diagnosis most often made by history and physical examination and is frequently a diagnosis of exclusion." | ( Bjarnason, D; Dlesk, A; Goldberg, JW; Lee, MK; Washington, WL, 1986) |
| "Joint damage in rheumatoid arthritis is assessed radiologically." | ( Coulton, BL; Popert, AJ; Scott, DL, 1986) |
| "Although rheumatoid arthritis is usually a chronic polyarthritis, it progresses in a wide variety of ways often with organ involvement." | ( Bird, HA, 1986) |
| "Rheumatoid arthritis is a chronic inflammatory synovitis that primarily involves peripheral diarthrodial joints." | ( Decker, JL; Haraoui, B; Klippel, JH; Malone, DG; Schrieber, L; Steinberg, AD; Wahl, SM; Wilder, RL, 1984) |
| "Rheumatoid arthritis is characterized by immunologically mediated chronic inflammation of synovial structures." | ( Lipsky, PE, 1983) |
| "Rheumatoid arthritis is associated with Dw4 and DR4 in Caucasians." | ( Stastny, P, 1983) |
| "Active rheumatoid arthritis is associated with increased numbers of plaque forming cells in the peripheral blood, changes in the numbers of these cells providing an index of disease activity." | ( Corke, CF; Gul, V; Holborow, EJ; Huskisson, EC, 1984) |
| "The pathogenesis of rheumatoid arthritis is unknown, but clear abnormalities of the immune system are well documented in this disease." | ( Goldstein, G; Hermanns, P; Kung, P; Schindler, J; Van Wauwe, J; Veys, EM, 1981) |
| "Canine rheumatoid arthritis is an uncommon diagnosis, and it is not the intent of this discussion to encourage either the use of cytotoxic drugs or the experimentation with unproven agents in dogs with vaguely defined forms of arthritis." | ( Romatowski, J, 1984) |
| "Rheumatoid arthritis is a very common disease with potentially serious disability in patients of all ages." | ( Dorwart, BB, 1984) |
| "Rheumatoid arthritis is a disease of variable natural history." | ( Barraclough, D, 1983) |
| "While rheumatoid arthritis is characteristically an indolent disease, failure to recognize its urgent complications can cause significant morbidity and mortality." | ( Weiner, SR, 1984) |
| "Rheumatoid arthritis is generally a symmetrical polyarthritis characteristically involving small joints." | ( Hamilton, S, 1983) |
| "Rheumatoid arthritis is a systemic disease in which anaemia is common." | ( Reinthaler, M; Singer, F, 1982) |
| "The anaemia in rheumatoid arthritis is apparently of complex origin, in which case an increased accumulation of iron in the RES and the decreased utilisation of storage iron play the quantitatively most important role." | ( Fischer, H; Herrmann, F, 1980) |
| "Rheumatoid arthritis is a chronic, progressive disease with a long-term outcome characterized by significant morbidity, loss of functional capacity, and increased mortality." | ( Semble, EL, 1995) |
| "Rheumatoid arthritis is a systemic inflammatory disease with a predilection for the synovial tissues." | ( Anastassiades, TP; Towheed, TE, 1994) |
| "Rheumatoid arthritis is the commonest connective tissue disease associated with bronchiolitis obliterans, a clinico-pathologic entity of bronchiolar inflammation and fibrosis reflecting injury to the small airways, and presenting with symptoms and signs of small airways obstruction." | ( Wong, R; Yam, LY, 1993) |
| "Rheumatoid arthritis is present in a population which is heterogeneous both clinically and immunologically." | ( Yocum, D, 1993) |
| "Elderly onset rheumatoid arthritis is a not rare disease with relevant social implications." | ( Bambara, LM; Biasi, D; Caramaschi, P; Carletto, A, 1995) |
| "Rheumatoid arthritis is a common disease that causes substantial morbidity and mortality." | ( Drymalski, W; Eckhoff, PJ; Erikson, N; Garwood, V; Haire, CE; Klassen, LW; Klein, H; Maloley, P; Moore, GF; O'Dell, JR; Palmer, W; Wees, S, 1996) |
| "Rheumatoid arthritis is a chronic inflammatory process of unknown etiology that leads to significant morbidity and accelerated mortality in the 10 to 15% of patients with severe proliferative and erosive synovitis that is unresponsive to conventional therapies." | ( Torley, H; Yocum, DE, 1995) |
| "Rheumatoid arthritis is a chronic immune-mediated disease characterised by an inflammatory synovitis and extra-articular manifestations." | ( Emery, P; Richardson, C, 1995) |
| "Rheumatoid arthritis is associated with numerous abnormalities measurable in a laboratory." | ( Emery, P; Richardson, C, 1996) |
| "Rheumatoid arthritis is characterized by a chronic hypertrophic synovitis leading to destruction of connective tissue and functional damage of cartilage and bone structures." | ( Borzì, RM; Facchini, A; Grigolo, B; Mazzetti, I; Meliconi, R, 1996) |
| "Azathioprine and rheumatoid arthritis are known to be associated with an increased risk of the development of non-Hodgkin's lymphoma; however, the manifestation of fulminant hepatic failure is extremely uncommon in patients with non-Hodgkin's lymphoma." | ( Aguilar, HI; Burgart, LJ; Geller, A; Rakela, J, 1997) |
| "Rheumatoid arthritis is a common systemic disease that affects between 0." | ( Janson, RW; Smyth, CJ, 1997) |
| "A patient with rheumatoid arthritis is described who presented with low-grade fever for 3 months, in whom Actinobacillus ureae was cultured from bone marrow aspirate." | ( Avlami, A; Dounis, E; Kordossis, T; Papalambrou, C; Tzivra, M, 1997) |
| "Rheumatoid arthritis is a common inflammatory articular disorder in Bangladesh." | ( Alam, MN; Ali, ML; Baral, PK; Das, KK; Haq, SA, 1997) |
| "Rheumatoid arthritis is a painful, chronic disease that affects an estimated 2 million Americans." | ( Alarcón, GS, 1999) |
| "Rheumatoid arthritis is a systemic disease of unknown etiology." | ( Bollen, A; Fuhrmann, SR; Gelderman, MP; Graham, S; Lefkowitz, DL; Lefkowitz, SS; Moguilevsky, N; Starnes, JD, 1999) |
| "Rheumatoid arthritis is a chronic inflammatory disease affecting about 1% of the adult population." | ( Bank, I; Langevitz, P; Livneh, A; Pras, M, 2000) |
| "Synovial tissue in rheumatoid arthritis is characterized by infiltration with large numbers of T lymphocytes and APCs as well as hyperplasia of synovial fibroblasts." | ( Chung, K; Endres, J; Fox, DA; Freiberg, A; Gupta, R; He, X; Morita, Y; Pai, R; Yamamura, Y, 2001) |
| "Four patients with rheumatoid arthritis are reported who developed acute myeloid leukemia (AML) while receiving low dose weekly methotrexate therapy in the absence of previous or concomitant treatment with known leukemogenic agents." | ( Baer, AN; Baer, MR; Barcos, M; Kolte, B; O'Loughlin, KL; Sait, SN; Stewart, CC; Wetzler, M, 2001) |
| "Osteoarthritis and rheumatoid arthritis are characterized by focal loss of cartilage due to an up-regulation of catabolic pathways, induced mainly by pro-inflammatory cytokines, such as interleukin-1 (IL-1) and tumour necrosis factor alpha (TNFalpha)." | ( Dolzani, P; Facchini, A; Grigolo, B; Mazzetti, I; Meliconi, R; Pulsatelli, L; Roseti, L; Silvestri, T, 2001) |
| "Rheumatoid arthritis is a chronic inflammatory disease with a progressive course, that frequently provokes permanent incapacity if not adequately treated." | ( Bambara, LM; Biasi, D; Canestrini, S; Caramaschi, P; Carletto, A; Scambi, C; Scarperi, A, 2002) |
| "Rheumatoid arthritis is a prevalent example of an inflammatory angiogenic disease, which is mediated by pro-inflammatory and pro-angiogenic cytokines such as tumor necrosis factor (TNF)." | ( An, P; Ding, I; Li, P; Liu, W; Min, W; Planelles, V; Schwarz, EM; Yin, G, 2002) |
| "Rheumatoid arthritis is a disease that, pathologically, is characterized by the progressive growth and invasion of the synovial pannus into the surrounding cartilage and bone." | ( Elkon, KB; Jun, JB; Kim, G, 2002) |
| "Rheumatoid arthritis is the autoimmune disorder most often associated with yellow nail syndrome." | ( Despaux, J; Lehuédé, G; Michel, F; Toussirot, E; Wendling, D, 2002) |
| "Active rheumatoid arthritis is associated with an adverse lipid profile that improves substantially following effective treatment of rheumatoid arthritis." | ( Choi, HK; Kim, DK; Kim, MY; Lee, SK; Lee, WK; Park, YB; Song, J, 2002) |
| "Rheumatoid arthritis is associated with chronic synovial inflammation due to the abnormal accumulation of macrophages and autoreactive T lymphocytes in joints." | ( Blankenberg, FG; Geaghan, SM; Katsikis, PD; Post, AM; Strauss, HW; Tait, JF, 2002) |
| "Rheumatoid arthritis is a common autoimmune disease characterized by inflammation of the synovial membrane of diarthrodial joints, which often leads to joint damage and disability." | ( Bridges, SL; Hughes, LB; Moreland, LW, 2002) |
| "Rheumatoid arthritis is a chronic inflammatory disease that primarily affects the joints and is often treated with non-steroidal anti-inflammatory drugs (NSAIDs) on demand and disease-modifying antirheumatic drugs (DMARDs), with a relatively low risk of side effects." | ( Bruyn, GA; Jansen, TL; Kalksma, R, 2002) |
| "Rheumatoid arthritis is a multifactorial disease that results in severe destruction of synovial cartilage and bone." | ( Soory, M, 2002) |
| "Bone destruction in rheumatoid arthritis is characterized as 'the defective control of bone metabolism by the immune system'." | ( Takayanagi, H, 2002) |
| "Rheumatoid arthritis is a chronic and debilitating disease, affecting an estimated 1% of the population worldwide." | ( Cannella, AC; O'Dell, JR, 2003) |
| "Rheumatoid arthritis is a systemic disease that causes inflammation and joint destruction." | ( Brzosko, I; Brzosko, M; Droździk, M; Gawrońska-Szklarz, B; Ostanek, L; Pawlik, A; Sterna, R, 2004) |
| "Rheumatoid arthritis is a severe, debilitating condition for which existing therapies are of limited efficacy." | ( Cole, P; Rabasseda, X, 2004) |
| "Rheumatoid arthritis is characterised by inflammatory synovitis, articular destruction, and accelerated atherogenesis." | ( Capell, HA; Ford, I; Hampson, R; Madhok, R; McCarey, DW; McInnes, IB; Sattar, N; Scherbakov, O, 2004) |
| "Rheumatoid arthritis is the most common inflammatory joint disease and is characterized by chronic, symmetric, erosive synovitis of small joints of hands and feet." | ( Häntzschel, H; Pierer, M; Seidel, W, 2004) |
| "Patients with rheumatoid arthritis are at high risk for acute myocardial infarction (AMI)." | ( Krishnan, E; Lingala, VB; Singh, G, 2004) |
| "1." | ( Blades, M; Brain, SD; Castro da Rocha, FA; Keeble, J; Pitzalis, C, 2005) |
| "Rheumatoid arthritis is a chronic inflammatory autoimmune disease with proinflammatory cytokines involved in its pathogenesis." | ( Boehme, MW; Gao, IK; Lemmel, EM; Norden, C, 2006) |
| "Rheumatoid arthritis is characterized by the presence of inflammatory synovitis and destruction of joint cartilage and bone." | ( Bezerra, MC; Carvalho, JF; Pereira, RM; Prokopowitsch, AS, 2005) |
| "Rheumatoid arthritis is a chronic multi-system disorder of unknown etiology with most common symptoms being persistent inflammatory synovitis, usually involving peripheral joints in a symmetrical pattern." | ( Derk, CT, 2005) |
| "When rheumatoid arthritis is the underlying cause, this outcome is more frequent among those with an acute episode of pericarditis during the course of the disease." | ( Abecasis, M; Aguiar, C; Andrade, MJ; Ferreira, J; Gomes, RS; Martins, AP; Pais, MJ; Ramos, S; Raposo, L; Reis, AB, 2005) |
| "Rheumatoid arthritis is a chronic inflammatory autoimmune disease of unknown cause." | ( Huizinga, TW; Ioan-Facsinay, A; Toes, RE; van Gaalen, F, 2005) |
| "Rheumatoid arthritis is a chronic inflammatory disease of unknown etiology, which is characterised by pain, loss of capability to work, in severe cases the life expectancy is also reduced." | ( Surányi, P, 2005) |
| "Rheumatoid arthritis is a chronic autoimmune inflammatory condition characterised by polyarthritis and severe change in body mass and neuroendocrine environment." | ( Dieguez, C; Gomez, R; Gómez-Reino, JJ; Gualillo, O; Lago, F; Lago, R; Otero, M, 2006) |
| "Rheumatoid arthritis is characterized by chronic synovitis resulting in bone and joint destruction in various delays, and ultimately leading to handicap." | ( Lioté, F, 2005) |
| "Rheumatoid arthritis is characterised by inflammation and an increased cardiovascular risk." | ( de Koning, MH; Dijkmans, BA; Habibuw, MR; Nielen, MM; Nurmohamed, MT; Reesink, HW; Twisk, JW; van de Stadt, RJ; van der Horst-Bruinsma, IE; van Halm, VP; van Schaardenburg, D; Voskuyl, AE, 2007) |
| "Many patients with rheumatoid arthritis are currently successfully treated with infliximab (anti-tumour necrosis factor); however, about 30% of the patients do not respond to infliximab." | ( Aarden, LA; de Groot, ER; Dijkmans, BA; Roos, JC; Stigter van Walsum, M; van der Laken, CJ; Voskuyl, AE; Wolbink, G, 2007) |
| "Active chronic rheumatoid arthritis is characterised by enhanced CCR2 density on circulating monocytes and CD4(+) CXCR3(+) and CD4(+) CXCR3(-) T lymphocytes." | ( Ellingsen, T; Hornung, N; Møller, BK; Poulsen, JH; Stengaard-Pedersen, K, 2007) |
| "Rheumatoid arthritis is a chronic inflammatory condition whose pathogenesis is determined partially by genetic and environmental factors." | ( Moszyk, DJ; Sulit, DJ, 2007) |
| "Rheumatoid arthritis is characterized by chronic inflammation of the synovial tissue." | ( Arima, Y; Ashino, T; Iwakura, Y; Numazawa, S; Shioda, S; Yoshida, T, 2007) |
| "Rheumatoid arthritis is one of the most common epidemic diseases in the world." | ( Chang, SJ; Chuang, KS; Hsueh, YW; Tsai, WP; Wang, JN; Wu, J; Yeh, KC, 2007) |
| "Rheumatoid arthritis is an inflammatory and disabling joint disease affecting 0." | ( Biswal, BK; Brömme, D; Cherny, M; James, MN; Weidauer, E; Yasuda, Y, 2007) |
| "Rheumatoid arthritis is a common and potentially devastating condition which did not have good treatment options until recently." | ( Fan, PT; Leong, KH, 2007) |
| "Rheumatoid arthritis is a chronic inflammatory disease in which early aggressive therapy with disease-modifying antirheumatic drugs can improve outcome and prevent joint damage." | ( Mitchell, KL; Pisetsky, DS, 2007) |
| "Today, rheumatoid arthritis is a prototype disease in this context as most compounds have been tried in this disease." | ( Szekanecz, Z; Tamási, L, 2007) |
| "Rheumatoid arthritis is a chronic autoimmune disease involving progressive destruction of the joints." | ( Gay, S; Ospelt, C, 2007) |
| "Rheumatoid arthritis is the most common cause of elbow arthritis, followed by posttraumatic arthritis and primary osteoarthritis." | ( Kwon, YW; Soojian, MG, 2007) |
| "Rheumatoid arthritis is the collagen diseases which most frequently associates ocular sicca syndrome in mild and medium clinical forms." | ( Bărăscu, D; Bârjovanu, F; Mocanu, C, 2007) |
| "Rheumatoid arthritis is a chronic inflammatory condition associated with increased cardiovascular risk." | ( Booth, AD; Brown, J; Hall, FC; Mäki-Petäjä, KM; McEniery, CM; Wallace, SM; Wilkinson, IB, 2007) |
| "Rheumatoid arthritis is a chronic disabling disease affecting at least 1% of the population on a worldwide basis." | ( Williams, RO, 2006) |
| "Rheumatoid arthritis is characterized by inflammation of the joints and degradation and invasion by fibroblast-like synoviocytes (FLS) of the cartilage." | ( Huizinga, TW; Tolboom, TC, 2007) |
| "Chronic gout and rheumatoid arthritis are common medical manifestations with debilitating effects on patients." | ( Baker, DL; Gilstrap, CA; Stroup, JS, 2007) |
| "Rheumatoid arthritis is characterized by chronic polyarthritis and destruction of multiple joints." | ( Denizli, A; Kalyoncu, U; Rad, AY; Unal, S; Uzun, L; Yilmaz, E, 2008) |
| "Rheumatoid arthritis is an autoimmune disease with an unknown etiology." | ( Hwang, IN; Hwang, YC; Oh, WM; Son, HH, 2008) |
| "Rheumatoid arthritis is a disease associated with painful joints that affects approximately 1% of the population worldwide, and for which no effective cure is available." | ( Mirshafiey, A; Mohsenzadegan, M, 2008) |
| "Rheumatoid arthritis is an autoimmune rheumatic condition of unknown origin." | ( Gergely, P; Poór, G, 2007) |
| "Pathogenesis of rheumatoid arthritis is likely to implicate anti-citrullinated protein/ peptide antibody(ACPA) and an immunodistortion including abnormal T cell subpopulation." | ( Kameda, H; Takeuchi, T, 2009) |
| "Rheumatoid arthritis is characterised by antibodies to citrullinated proteins (ACPA) and rheumatoid factor (RF) in the preclinical phase." | ( Boers, M; Bos, WH; Dijkmans, BA; van de Stadt, RJ; van Schaardenburg, D, 2010) |
| "Rheumatoid arthritis is one of most common chronic diseases, and represents a high cost for the health system." | ( Díaz, J; González, A; Mora, C; Quintana, G, 2009) |
| "Rheumatoid arthritis is not uncommon among Nigerian; and clinical, serologic acumen are necessary for early diagnosis and appropriate referral." | ( Adelowo, OO; Oduenyi, I; Ojo, O; Okwara, CC, 2010) |
| "Dyslipidaemia in rheumatoid arthritis, is associated with accelerated atherosclerosis." | ( Biswas, A; Ghosh, UC; Kundu, AK; Roy, A; Saha, I; Sen, K, 2009) |
| "Rheumatoid arthritis is a systemic disease that often affects the foot and ankle (85%-100% of patients)." | ( Moosig, F; Niggemeyer, O; Rüther, W, 2011) |
| "Rheumatoid arthritis is a chronic inflammatory condition that affects mainly synovial joints and has an impact on approximately 1% of the Western population." | ( Oberholzer, HM; Pretorius, E; Soma, P; Swanepoel, AC; van der Spuy, WJ, 2012) |
| "Rheumatoid arthritis is associated with the development of autoantibodies to citrullinated self-proteins." | ( Arend, WP; Banda, NK; Causey, CP; Chandra, P; Cordova, KN; Gizinski, AM; Glogowska, M; Holers, VM; Knuckley, B; Kulik, L; Levitt, B; Luo, Y; Robinson, WH; Thompson, PR; Willis, VC, 2011) |
| "Rheumatoid arthritis is well known for multiple extra-articular manifestations." | ( Guerne, PA; Horvath, J; Huys, AC, 2012) |
| "Rheumatoid arthritis is an autoimmune disease that primarily affects the limbs, but the pathogenic mechanism remains unclear." | ( Chen, X; He, D; Hu, C; Huang, Q; Liu, B; Miao, P; Miao, Y; Nie, H; Qian, L; Wang, P; Xu, R; Yu, Q; Zhang, D; Zhang, J, 2012) |
| "Rheumatoid arthritis is a chronic autoimmune disease characterised by inflammation of joints with cartilage and bone destruction leading to progressive disability." | ( Blueml, S; Bonelli, M; Hayer, S; Hladik, A; Niederreiter, B; Puchner, A; Redlich, K; Scheinecker, C; Smolen, J, 2012) |
| "Rheumatoid Arthritis is a chronic inflammatory disease resulting in joint inflammation (particularly joints of hands, wrists, feet, knees, ankles, and shoulder) that is manifested by swelling and functional impairment." | ( Afridi, HI; Kazi, N; Kazi, TG; Khan, S; Kolachi, NF; Shah, AQ; Shah, F; Wadhwa, SK, 2012) |
| "Diagnosing early rheumatoid arthritis is difficult and radiographic signs are often late." | ( Charfi, O; Cheour, E; Elleuch, M; Meddeb, N; Mizouni, H; Mnif, E; Mrabet, D; Sahli, H; Sellami, S, 2012) |
| "Rheumatoid arthritis is a destructive arthropathy characterized by chronic synovial inflammation that imposes a substantial socioeconomic burden." | ( Aidinis, V; Armaka, M; Gay, S; Karouzakis, E; Kollias, G; Masu, M; Mersinias, V; Mills, GB; Nikitopoulou, I; Nikolaidou-Katsaridou, N; Oikonomou, N; Sevastou, I; Xu, Y; Zhao, Z, 2012) |
| "Rheumatoid arthritis is characterized by systemic inflammation of synovial joints leading to erosion and cartilage destruction." | ( Colombo, S; Foged, C; Jensen, LB; Lammers, T; Nicolay, K; Nielsen, HM; Schiffelers, RM; Storm, G; Strijkers, GJ; te Boekhorst, BC; Varkouhi, AK, 2012) |
| "Rheumatoid arthritis is characterized by the imbalance of T cells, which leads to increased pro-inflammatory and reduced anti-inflammatory cytokines." | ( Chen, YY; Fu, HZ; Hu, J; Lu, Y; Qian, RQ; Wang, ZM; Wu, ZW; Xiao, J, 2012) |
| "Evolution to rheumatoid arthritis is common, especially in patient with positive rheumatoid factor and anticitrullinated peptides." | ( Soubrier, M; Tatar, Z; Vayssade, M, 2013) |
| "Osteoarthritis and rheumatoid arthritis are conditions that are associated with significant clinical burden, and impact on patients' functional status and quality of life." | ( Foster, TS; Huelin, R; Mould, JF; Pokora, T, 2012) |
| "Rheumatoid arthritis is an inflammatory, autoimmune disease where oxidative stress has been proposed to contribute to the joint tissue damage." | ( Chatterjee, M; Chattopadhyay, S; Datta, S; Ghosh, A; Ghosh, P; Kundu, S, 2012) |
| "The pathogenesis of rheumatoid arthritis is mainly driven by NF-κB-mediated production of cytokines, such as TNF-α." | ( Azevedo, LM; Cornicelli, JA; Henry, RW; Hovde, S; Kahlon, DK; Lansdell, TA; McCormick, JJ; O'Reilly, S; Tepe, JJ; Woolliscroft, T, 2012) |
| "Rheumatoid arthritis is an autoimmune arthritis characterized by joint destruction." | ( Bennin, DA; Huttenlocher, A; Mosher, DF; Shelef, MA, 2012) |
| "Patients with rheumatoid arthritis are at higher risk for serious infections and death from infection than the general public." | ( Winthrop, KL, 2012) |
| "Rheumatoid arthritis is characterized by early and accelerated atherosclerosis leading to increased cardiovascular morbidity and mortality." | ( Aslanidis, S; Doumas, M; Gavriilaki, E; Gkaliagkousi, E; Petidis, K; Stella, D, 2012) |
| "Rheumatoid arthritis is an autoimmune disorder characterized by persistent synovitis and systemic inflammation." | ( Antoniazzi, S; Borsadoli, C; Carnovale, C; Clementi, E; Froldi, G; Magistro, L; Mambrini, A; Perrone, V; Radice, S; Speziali, A, 2013) |
| "Rheumatoid arthritis is a heterogeneous chronic disease, and no therapeutic agent has been identified which is universally and persistently effective in all patients." | ( Benda, B; Blanco, R; Bradley, J; Burmester, GR; Charles-Schoeman, C; Gruben, D; Koncz, T; Krishnaswami, S; Mebus, C; Soma, K; Wallenstein, G; Wollenhaupt, J; Zerbini, C; Zwillich, SH, 2013) |
| "Rheumatoid arthritis is an autoimmune disorder which involves inflammation of the synovial tissue, leading to synovial proliferation, bone erosion and ultimately joint disability." | ( Bhatti, A; John, P; Moeez, S, 2013) |
| "Rheumatoid arthritis is a disease showing considerable heterogeneity in all its aspects, including response to therapy." | ( Coenen, MJ; Umićević Mirkov, M, 2013) |
| "Rheumatoid arthritis is a widespread autoimmune disease." | ( Bräuer, R; Frommholz, D; Gajda, M; Illges, H; Nent, E, 2013) |
| "Rheumatoid arthritis is a chronic inflammatory disease characterized by synovial hyperplasia and progressive joint destruction." | ( Li, H; Wan, A, 2013) |
| "Rheumatoid arthritis is a chronic inflammatory disease with a strong MHC class II component and where many patients develop characteristic autoantibodies towards the noncoding amino acid citrulline." | ( Herrath, J; Malmström, V; Muhammad, K; Pieper, J; Raghavan, S; Vollenhoven, Rv, 2013) |
| "Rheumatoid arthritis is most prominently characterized by synoviocyte hyperplasia which therefore serves as an important target for clinical therapy." | ( Hu, F; Pan, L; Sun, Y; Wang, X; Wang, Y; Yang, S; Zhu, S, 2014) |
| "Rheumatoid arthritis is a chronic inflammatory and autoimmune disease that leads to aggressive joint cartilage and bone destruction." | ( Ignacimuthu, S; Islam, VI; Paulraj, MG; Pazhanivel, N; Raghuraman, N; Saravanan, S; Thirugnanasambantham, K, 2014) |
| "Rheumatoid arthritis is an autoimmunity leading to considerable impairment of quality of life." | ( Capková, K; Danyi, I; Fišerová, A; Hříbalová, V; Malý, M; Richter, J; Vannucci, L, 2014) |
| "Rheumatoid arthritis is a chronic inflammatory disease characterized by overproduction of inflammatory mediators along with undermined oxidative defensive mechanisms." | ( El-Azab, MF; El-Sayed, RM; Moustafa, YM, 2014) |
| "Rheumatoid arthritis is an inflammatory disease with high incidence of cardiovascular disease due to accelerated atherosclerosis." | ( Balsa, A; Blanco, R; Carreira, P; Castañeda, S; Corrales, A; Fernández-Gutiérrez, B; García-Bermúdez, M; Genre, F; Gómez-Vaquero, C; González-Álvaro, I; González-Gay, MA; González-Juanatey, C; Llorca, J; López-Longo, FJ; López-Mejías, R; Martín, J; Miranda-Filloy, JA; Pascual-Salcedo, D; Pina, T; Rodríguez-Rodríguez, L; Ubilla, B, 2014) |
| "A key phenomenon in rheumatoid arthritis is the formation of lymphoid follicles in the inflamed synovial membrane." | ( Deleuran, B; Greisen, SR; Hetland, ML; Hvid, M; Hørslev-Petersen, K; Junker, P; Kragstrup, TW; Rasmussen, TK; Schelde, KK; Stengaard-Pedersen, K; Østergaard, M, 2014) |
| "Rheumatoid arthritis is a chronic systemic disease that causes joint damage." | ( Batista, DA; Lopes, M; Meireles, SM; Natour, J; Skare, TL, 2014) |
| "Rheumatoid arthritis is an inflammatory autoimmune disorder." | ( Ahmed, RS; Arora, VK; Banerjee, BD; Khan, MA; Subramaneyaan, M, 2015) |
| "Rheumatoid arthritis is a systemic inflammatory disease characterized by synovitis and the destruction of articular structures in multiple joints." | ( Bandoh, S; Dobashi, H; Imataki, O; Izumikawa, M; Kameda, T; Morimoto, H; Nakashima, S; Shimada, H; Susaki, K; Takeuchi, Y, 2015) |
| "Osteoarthritis and rheumatoid arthritis are the two most common types of arthritis." | ( Laev, SS; Salakhutdinov, NF, 2015) |
| "Rheumatoid arthritis is a systemic autoimmune disease characterized by chronic inflammation of multiple joints, with disruption of joint cartilage." | ( Cen, XM; Li, Y; Xie, QB; Yang, M; Yin, G, 2015) |
| "Rheumatoid arthritis is an autoimmune disease characterized by joint inflammation that affects approximately 1% of the general population." | ( Aira, LE; Chico, A; Fuentes, K; Gómez, JA; González, Z; Hernández, P; Mazorra, Z; Prada, D; Viada, C, 2016) |
| "Rheumatoid arthritis is a chronic systemic inflammatory disease characterized by synovitis, erosions, and destruction of affected joints." | ( Čulo, MI; Gudelj Gračanin, A; Marković, I; Mitrović, J; Morović-Vergles, J; Pukšić, S, 2015) |
| "Rheumatoid arthritis is a chronic inflammatory disease that leads to bone and cartilage erosion." | ( Deng, Y; Dong, Y; Geng, X; Li, A; Lu, T; Peng, X; Yang, L, 2015) |
| "Rheumatoid arthritis is a systemic autoimmune disease characterized by joint erosions, progressive focal bone loss, and chronic inflammation." | ( Fuchs, D; Herold, M; Klotz, W; Kurz, K; Russe, E; Weiss, G, 2015) |
| "Rheumatoid Arthritis is a chronic disease leading to decreased quality of life with a rather variable response rate to Disease Modifying Anti Rheumatic Drugs." | ( Gál, J; Lőrincz, A; Micsik, T; Peták, I; Schwab, R, 2015) |
| "Rheumatoid arthritis is a debilitating autoimmune disease of the joints which affects many people worldwide." | ( Cavaco-Paulo, A; Gomes, AC; Nogueira, E; Preto, A, 2016) |
| "Rheumatoid arthritis is a chronic inflammatory disease." | ( Arsic, A; Djuric, D; Jakovljevic, V; Jeremic, N; Jovanovic, M; Lucic-Tomic, A; Vasiljevic, D; Veselinovic, M; Vucic, V; Zivanovic, S, 2016) |
| "Rheumatoid arthritis is a chronic, highly disabling autoimmune disease that requires aggressive pharmacological treatment using immunomodulatory drugs grouped under the name of Disease-Modifying Anti-rheumatic Drugs (DMARDs)." | ( Molina Molina, MI; Pinochet Paiva, CM; Quezada Morales, JI, 2015) |
| "Rheumatoid arthritis is a systemic inflammatory condition associated with increased cardiovascular risk that may be due to underlying endothelial dysfunction and subsequent aortic stiffening." | ( Cheriyan, J; Day, L; Hall, FC; Mäki-Petäjä, KM; Östör, AJ; Shenker, N; Wilkinson, IB, 2016) |
| "Individuals with rheumatoid arthritis are at higher risk for infection than the general population, and surgical site infection after spinal surgery in this population can result in clinically significant complications." | ( Ebata, S; Haro, H; Koyama, K; Ohba, T, 2016) |
| "Rheumatoid arthritis is a common chronic inflammatory and destructive arthropathy that consumes considerable personal, social and economic costs." | ( Cavaco-Paulo, A; Gomes, A; Nogueira, E; Preto, A, 2016) |
| "Rheumatoid arthritis is a chronic autoimmune pathology characterized by the proliferation and inflammation of the synovium." | ( Bruno, LJ; Castillo, J; Feldman, S; Garabalino, MA; Gatti, DA; Hughes, AM; Pozzi, EC; Schwint, AE; Scolari, H; Stur, M; Trivillin, VA; Wentzeis, L, 2016) |
| "Rheumatoid arthritis is the most common inflammatory rheumatic disease." | ( Fiehn, C; Krüger, K, 2016) |
| "Rheumatoid arthritis is a progressive, highly debilitating disease where early diagnosis, enabling rapid clinical intervention, would provide obvious benefits to patients, healthcare systems, and society." | ( Critchlow, SE; Firth, MA; Karagianni, N; Kollias, G; Michopoulos, F; Nikolaou, C; Theodoridis, GA; Whalley, NM; Wilson, ID, 2016) |
| "Rheumatoid arthritis is a systemic, chronic disease which may increase the risk of osteoporosis." | ( Aryaeian, N; Djalali, M; Shahram, F, 2016) |
| "Rheumatoid arthritis is an autoimmune disorder that affects the joints and other organs." | ( Bradley, CP; Felix, KM; Naskar, D; Teng, F; Wu, HJ, 2017) |
| "Rheumatoid arthritis is a systemic auto-immune disorder that causes widespread and persistent inflammation of the synovial lining of joints and tendon sheaths." | ( Fidahic, M; Jelicic Kadic, A; Puljak, L; Radic, M, 2017) |
| "Rheumatoid arthritis is a systemic disorder where clinically significant renal involvement is relatively common." | ( Balendran, K; Lanerolle, RD; Senarathne, LDSU, 2017) |
| "Rheumatoid arthritis is thought to induce conductive hearing loss and/or sensorineural hearing loss." | ( Ahmadzadeh, A; Amini, E; Daneshi, A; Daraei, M; Jalessi, M; Peyvandi, AA; Ranjbar, LA, 2017) |
| "Rheumatoid arthritis is a chronic autoimmune disease characterized by an elevated synovial inflammatory response, with destruction or erosion of articular cartilage in major joints." | ( Li, Y; Liu, ZX; Sun, XH; Sun, Y; Zhao, DL, 2017) |
| "Rheumatoid arthritis is a common autoimmune disease, however, available regimes exert little influence on it's long-term prognosis." | ( Ji, CL; Jiang, H; Jiang, J; Tao, MQ; Wu, WT; Zuo, J, 2017) |
| "Rheumatoid arthritis is a chronic autoimmune disease hallmarked by inflammation in synovial joints." | ( Becker, JU; Becker, KA; Beckmann, N; Carpinteiro, A; Fassbender, K; Göthert, JR; Gulbins, E; Hessler, G; Kramer, M; Walter, S; Weber, S, 2017) |
| "Rheumatoid arthritis is a chronic disease of the joints, which causes joint pain and disability." | ( Colares, VLP; Fernandes, AMR; Fernandes, ES; Martins, MMRS; Mendes, SJF; Monteiro, CRAV; Muniz, TF; Pereira, DMS; Pereira, ICP; Silva, BLR; Sousa, NCF, 2018) |
| "Rheumatoid arthritis is a widespread autoimmune disease and inflammation and bone destruction are two main issues in rheumatoid arthritis." | ( Haybar, H; Mowla, K; Rajaei, E; Zayeri, ZD, 2019) |
| "Rheumatoid arthritis is an inflammatory polyarthritis that frequently affects the hands and wrists." | ( Brosseau, L; Bruce, J; Heine, PJ; Hoxey-Thomas, N; Lamb, SE; Srikesavan, C; Williams, MA, 2018) |
| "Rheumatoid arthritis is the most common inflammatory autoimmune disease in the world." | ( Araujo, GR; da Silva, HS; de Oliveira, DA; de Rezende Rodovalho, V; Flauzino, JMR; Madurro, AGB; Madurro, JM; Vaz, ER; Vieira, CU, 2018) |
| "Rheumatoid arthritis is a disease in which markers of telomere shortening and elevated oxidant stress correlate with disease activity." | ( Abdelaziz, MM; Elnaggar, MG; Emad, Y; Furst, DE; Gamal, RM; Hammam, N; Mohamed, MSE; Razek, MRA; Zakary, MM, 2018) |
| "BACKGROUND Rheumatoid arthritis is an autoimmune disease that causes chronic joint inflammation and there is no cure." | ( Mao, R; Song, L; Song, Y; Wang, C; Wang, X, 2018) |
| "Rheumatoid arthritis is characterized by progressive joint inflammation and affects ~1% of the human population." | ( Arandjelovic, S; Bettina, AM; Chuang, TY; Cohen, AH; Conrads, TP; Elliott, MR; Gaultier, A; Kim, M; Kim, TH; Lucas, CD; Penberthy, KK; Perry, JSA; Ravichandran, KS; Rosen, DA; Shankman, LS; Zhou, M, 2019) |
| "Rheumatoid arthritis is usually accompanied by various comorbidities especially on the psychological side such as depression." | ( Fawzy, HM; Gad, AM; Kamel, KM; Mansour, SM; Safar, MM, 2019) |
| "Rheumatoid arthritis is a risk factor for early mortality due to cardiovascular disease." | ( Andrade, MV; Kakehasi, AM; Pinto, MRC; Rocha, MA; Souza, AJ; Tavares, WC; Trant, CGMC, 2019) |
| "Rheumatoid arthritis is linked with altered host immune responses and severe joint destruction." | ( Colas, RA; Curtis, MA; Dalli, J; Flak, MB; Muñoz-Atienza, E; Pitzalis, C, 2019) |
| "Rheumatoid arthritis is a chronic and systemic autoimmune disease, which affects approximately 1% of the adult population worldwide." | ( Gao, M; Huang, Q; Huang, Z; Zheng, C; Zheng, J, 2020) |
| "Rheumatoid arthritis is an autoimmune disease that leads to cartilage destruction, synovial joint inflammation, and bacterial joint/bone infections." | ( Janakiraman, K; Kandasamy, R; Krishnaswami, V; Natesan, S; Rajendran, V; Sethuraman, V, 2019) |
| "Rheumatoid arthritis is the prototype of arthropathies." | ( Doria, A; Moroni, G; Ponticelli, C, 2021) |
| "Rheumatoid arthritis is a world leading cause of musculoskeletal disease." | ( Singh, S, 2020) |
| "Rheumatoid arthritis is a chronic inflammatory condition, which aggravates insulin resistance, placing the patients at a higher risk of type 2 diabetes and subsequent cardiovascular outcomes." | ( Baghdadi, LR, 2020) |
| "Rheumatoid arthritis is an autoimmune disorder causing joint deformity and work disability." | ( Pery, N; Rizvi, NB; Shafiq, MI, 2020) |
| "Rheumatoid arthritis is a chronic inflammatory disease which could lead to severe joint damage and disability." | ( Li, Z; Wu, Q; Xu, D; Zhang, Z; Zhao, Y, 2020) |
| "Key Points • Rheumatoid arthritis is a disease with a high burden of comorbidities, complications, and worse health-related quality of life and is associated with elevated healthcare costs." | ( Gamboa, NC; Gaviria-Mendoza, A; Machado-Alba, JE; Machado-Duque, ME; Reyes, JM, 2021) |
| "Rheumatoid arthritis is a rheumatic disease for which a healing treatment does not presently exist." | ( Gonçalves, C; Khang, G; Lee, S; Oliveira, IM; Oliveira, JM; Reis, RL; Shin, ME, 2020) |
| "Rheumatoid arthritis is a chronic systemic disease characterised by an unknown aetiology of inflammatory synovitis." | ( Miao, Y; Sun, J; Wang, X; Yang, J; Yun, Y, 2021) |
| "Rheumatoid arthritis is a chronic autoimmune disease characterised by joint synovial inflammation, along with cartilage and bone tissue destruction." | ( da Silva Morais, A; Gonçalves, C; González-Fernández, Á; Oliveira, EP; Oliveira, IM; Oliveira, JM; Reis, RL; Simón-Vázquez, R, 2021) |
| "Rheumatoid arthritis is a common autoimmune disease that requires new therapeutic agents." | ( Horimoto, Y; Murakami, F; Saito, M; Shimizu, H; Tada, K; Tamura, N; Yamaji, K, 2021) |
| "Rheumatoid arthritis is frequently associated with hypertension, which has been shown to increase the risk of cardiovascular disease in these patients." | ( Barra, L; Hadwen, B; Stranges, S, 2021) |
| "Rheumatoid arthritis is commonly associated with synovitis of the hands." | ( Bollow, M, 2021) |
| "Rheumatoid arthritis is a chronic, systemic inflammatory disease that carries an increased risk of mortality due to cardiovascular disease." | ( Chen, J; Cooper, D; Norling, LV, 2021) |
| "Rheumatoid arthritis is a kind of chronic crippling disease, the condition is complex, the course of the disease is repeated, seriously affecting the quality of life of patients." | ( Nie, C; Wang, P; Yu, J; Zheng, B, 2021) |
| "Rheumatoid arthritis is a systemic autoimmune disorder involved in persistent synovial inflammation." | ( Huang, DN; Sun, H; Wang, XJ; Wu, FF; Zhang, AH, 2021) |
| "Rheumatoid arthritis is an inflammatory arthropathy, autoimmune in nature, leading to disability of joints involving structural destruction of articular bone and cartilage due to inflammation in synovium resulting in joint stiffness, swelling and pain." | ( Aslam, B; Faisal, MN; Muhammad, F; Siddique, R, 2021) |
| "Rheumatoid arthritis is an inflammatory disease with joint manifestations." | ( da Costa, RL; de Freitas Calixto, L; de Freitas Netto, F; de Oliveira Toledo Júnior, A; Dos Santos, FA; Grassiolli, S; Mansani, FP; Montes, EG; Schafranski, MD; Vellosa, JCR; Zardo, BQ, 2021) |
| "Rheumatoid arthritis is a common autoimmune disease with many extra-articular manifestations." | ( Abeygunawardena, S; Jayalath, T; Karunathilake, P; Ralapanawa, U; Rathnayaka, M; Weerasinghe, S, 2021) |
| "Rheumatoid arthritis is a chronic and idiopathic autoimmune disorder." | ( Abubakar, M; Chamundeswari, D; Chaudhary, A; Gangasani, JK; Jain, S; Naidu, VGM; Np, S; Puppala, ER; Rachamalla, M; Saha, P; Usn, M; Yalamarthi, SS, 2022) |
| "Rheumatoid arthritis is an autoimmune disorder." | ( Kadu, P; Kale, P; Kulkarni, D; Naik, J; Pandya, A, 2022) |
| "Rheumatoid arthritis is primarily associated with inflammation and increased level of proinflammatory cytokines which are released by immune cells, macrophages or activation of arachidonic acid metabolism." | ( Akhter, S; Irfan, HM; Jahan, S; Latif, MB; Shahzad, M, 2022) |
| "Rheumatoid arthritis is a chronic inflammatory disease of unknown etiology marked by a symmetrical peripheral polyarthritis." | ( Goyal, L; Malode, A; Mathur, A; Yadav, R, 2022) |
| "Rheumatoid arthritis is the most common autoimmune disease worldwide and requires long-term treatment to suppress inflammation." | ( Allaart, CF; Boer, AC; Böhringer, S; Burgers, LE; Dakkak, YJ; de Jong, PHP; de Witt-Luth, ME; Huizinga, TWJ; Kok, MR; Krijbolder, DI; Molenaar, ETH; Niemantsverdriet, E; Park, YJ; van der Helm-van Mil, AHM; van Dijk, BT; Verstappen, M; Visser, K, 2022) |
| "Rheumatoid arthritis is the most common autoimmune, destructive, inflammatory arthritis in adults." | ( Singh, JA, 2022) |
| "Rheumatoid arthritis is a highly heterogeneous autoimmune disease characterized by unpredictable disease flares and significant differences in therapeutic response to available treatments." | ( Cheng, T; Li, XF; Liu, J; Qiao, J; Song, S; Zhang, SX; Zhao, R, 2022) |
| "Rheumatoid arthritis is an autoimmune disease that affects joints, leading to swelling, inflammation, and dysfunction in the joints." | ( Abdel-Reheim, MA; Ahmed Gaafar, AG; Atwa, GMK; Cavalu, S; El-Daly, M; Morsy, MA; Saber, S; Yahya, G; Youssef, ME, 2022) |
| "The development of rheumatoid arthritis is directly correlated with the disturbance of gut microbiome and its metabolites." | ( Cheng, B; Feng, LL; Guo, BJ; Guo, HW; He, Y; Huang, Z; Nong, YY; Qin, JH; Su, ZH; Wang, QY; Zhu, D, 2023) |
| "Osteoarthritis and rheumatoid arthritis are debilitating conditions, affecting millions of people." | ( Freeman, JW; Mann, A; Perry, B; Reiter, MP; Tiku, ML; Ward, SH, 2022) |
| "Rheumatoid arthritis is a common autoimmune disease that results from the deposition of antibodies-autoantigens in the joints, leading to long-lasting inflammation." | ( Chen, Y; Hu, W; Li, SF; Liang, HY; Yin, HX; Zhao, YJ; Zhou, RP, 2022) |
| "Rheumatoid arthritis is the most prevalent systemic autoimmune disease among the rheumatic inflammatory musculoskeletal diseases." | ( Feng, X; Liu, J; Liu, Y; Wang, Y; Wang, Z; Yang, L; Zhang, M; Zhang, X; Zhao, D, 2022) |
| "Rheumatoid arthritis is a chronic systemic inflammatory disease with genetic manifestations." | ( Aftab, U; Akhtar, T; Hussain, S; Khan, MUA; Naseem, N; Shahzad, M, 2023) |
| "Rheumatoid arthritis is among the most common disabling diseases associated with chronic inflammation." | ( Bergonzi, MC; Berrino, E; Bilia, AR; Bogani, I; Carta, F; Ghelardini, C; Mannelli, LDC; Micheli, L; Supuran, CT; Vanti, G, 2023) |
| "Rheumatoid arthritis is a chronic progressive autoimmune disorder, characterised by destruction of cartilage and under line bones." | ( Ahmad, M; Anwar, MF; Khan, MA, 2023) |
| "Patients with rheumatoid arthritis are prone to developing diabetes, which may lead to various sequelae and even cardiovascular diseases, the most common cause of death in such patients." | ( Chan, TM; Chen, HM; Chen, JF; Cheng, TT; Hsu, CY; Lin, CY; Su, YJ; Yu, SF, 2023) |
| "Rheumatoid arthritis is a systemic disease characterized by progressive chronic inflammation resulting in destruction of synovial joints." | ( Chen, K; Huang, X; Wang, Y; Xie, H; Yao, G; Zhu, Y, 2023) |
| "Mortality in rheumatoid arthritis is increased, about twice vs controls, and cardiovascular diseases are a major cause." | ( Schattner, A, 2023) |
| "Rheumatoid arthritis is considered a chronic systemic autoimmune disorder that may cause joint destruction." | ( Deng, AP; Fu, TX; Qiu, Q; Xie, XY; Zeng, HL, 2023) |
| "Rheumatoid arthritis is systemic inflammatory disease, presenting as symmetrical polyarthritis, mainly affecting hands and feet." | ( Jingzhou, Z; Xin, KQ; Xiong, Z, 2023) |
| "Rheumatoid arthritis is an autoimmune disease characterized by chronic polyarticular pain, for which no cure currently exists." | ( Bai, S; Han, X; Lan, Y; Li, A; Li, L; Song, Q; Wang, H; Wang, R, 2023) |
| Excerpt | Reference |
|---|
| "Benorylate is suitable for the treatment of recent rheumatoid arthritis of a low to moderate activity as well as for long-term treatment." | ( Müller-Fassbender, H; Schattenkirchner, M, 1975) |
| "Chrysotherapy is beneficial in the treatment of rheumatoid arthritis, but gold-induced aplastic anemia may be fatal." | ( Parker, WA; Shearer, CA, 1978) |
| "The drugs were equally effective in the treatment of rheumatoid arthritis while the incidence of indomethacin side-effects was 1." | ( Hearron, MS; Miyara, A; Moxley, TE; Royer, GL; Shenker, BM, 1975) |
| "D-Penicillamine treatment in rheumatoid arthritis resulted in a fall in plasma alfa-1-antitrypsin-IgA complexes which was significantly more pronounced among responders than among non-responders." | ( Jeppsson, JO; Laurell, CB; Wollheim, FA, 1979) |
| "Apart from the conventional treatment of the rheumatoid arthritis with steroidal and non-steroidal antirheumatic remedies, physiotherapy and balneotherapy as well as orthopaedic and surgical measures the basis therapy is an important factor." | ( , 1977) |
| "The use of penicillamine in the treatment of rheumatoid arthritis and scheroderma is reviewed." | ( Baum, J, 1979) |
| "For years the treatment of rheumatoid arthritis has been based on the assumption that the autoimmune processes and bone lesions occuring in rheumatic patients are due to inflammatory and immune reactions." | ( Symoens, J, 1977) |
| "The drugs mainly used for basical treatment of rheumatoid arthritis are cytostatics, D-penicillamine, gold salts and chloroquine." | ( Müller, AE; Thiele, HG, 1976) |
| "Chloroquine treatment of rheumatoid arthritis in the absence of any other disease which may cause retinopathy implies negligible risks in adult patients under 50 years of age." | ( Elman, A; Gullberg, R; Nilsson, E; Rendahl, I; Wachtmeister, L, 1976) |
| "Salicylates form the basis of drug treatment in rheumatoid arthritis." | ( Barraclough, DR; Laby, B; Muirden, KD, 1975) |
| "Aspirin is still the preferred treatment for rheumatoid arthritis and should be tried before ibuprofen." | ( Biundo, JJ; Gum, OB; Weiss, TE, 1976) |
| "The efficacy of naproxen in treating rheumatoid arthritis patients was evaluated in a double-blind clinical trial using aspirin as the control drug." | ( Bowers, DE; Dyer, HR; Fosdick, WM; Keller, KE; Rosenberg, AL; Sussman, P; Vancil, ME, 1975) |
| "The use of multiple drugs in treating rheumatoid arthritis is based on the assumption that their effects are additive." | ( Muirden, KD, 1976) |
| "The approach to the treatment of rheumatoid arthritis is currently undergoing fundamental change." | ( Jaffe, IA, 1992) |
| "Hydroxychloroquine is used for the treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)." | ( Littlejohn, GO; McCloud, PI; Morand, EF, 1992) |
| "Gold salts are still a first choice for treatment of rheumatoid arthritis." | ( Beyner, F; Buss, W; Ott, H; Van Linthoudt, D, 1991) |
| "Bucillamine is a useful medication for treatment of rheumatoid arthritis (RA) but some patients develop side effects from it." | ( Amasaki, Y; Atsumi, T; Fujisaku, A; Jodo, S; Kobayashi, H; Mukai, M; Nakabayashi, T; Nakagawa, S; Sagawa, A; Watanabe, I, 1991) |
| "A 54-year-old woman under treatment for rheumatoid arthritis was admitted because of aggravation of dyspnea on effort and restrictive pulmonary dysfunction." | ( Ichijima, K; Iwata, T; Kobashi, Y; Kohri, Y; Mino, M; Nambu, Y; Oida, K; Taguchi, Y; Tomii, K; Yunoki, Y, 1991) |
| "A 53-year male patient, treated for rheumatoid arthritis with sulphasalazine, developed a total agranulocytosis." | ( Jonson, B; Kanerud, L; Palmblad, J, 1990) |
| "MTX is an effective treatment of rheumatoid arthritis." | ( Willkens, RF, 1990) |
| "Accordingly, we surveyed 393 AZA-treated rheumatoid arthritis (RA) patients, who were recruited and enrolled through a nationwide call to rheumatologists." | ( Fries, JF; Singh, G; Spitz, P; Williams, CA, 1989) |
| "We conclude that during treatment of rheumatoid arthritis with gold, penicillamine or sulphasalazine, SAA concentrations can be high when serum CRP and ESR are suppressed." | ( Bacon, PA; Grindulis, KA; McConkey, B; Robinson, MW; Scott, DL, 1985) |
| "The drugs used in the treatment of rheumatoid arthritis are divided into two classes: a "first aid" and a "back up" group." | ( Lanciani, P, 1985) |
| "Sulphasalazine is an effective treatment for rheumatoid arthritis but the response in any individual is unpredictable." | ( Amos, RS; Bax, DE; Greaves, MS, 1986) |
| "Of a large importance in the treatment of the rheumatoid arthritis and of the osteoarthrosis is the method of clinical tests of non-steroidal antirheumatic drugs and of the so-called disease-activity modifying substances." | ( Pavelka, K; Trnavský, K, 1987) |
| "Numerous drugs are available for the treatment of rheumatoid arthritis." | ( Pinals, RS, 1988) |
| "The majority of patients were being treated for rheumatoid arthritis." | ( Kay, A, 1986) |
| "The possibility is raised that gold treatment of rheumatoid arthritis patients induces or enhances the formation of platelet-specific autoantibodies, and that gold-induced thrombocytopenia is a drug-induced autoimmune disease." | ( Helmerhorst, FM; Pegels, JG; van der Plas-van Dalen, CM; van der Stadt, RJ; von dem Borne, AE, 1986) |
| "Searching for new long-term treatments of rheumatoid arthritis (RA) is taking now different turns." | ( Crouzet, J, 1988) |
| "The efficacy of gold treatment in rheumatoid arthritis is hampered by toxicity, most prevalent in early phases, and unresponsiveness which can only be assessed after more than 6 months on therapy." | ( Wollheim, FA, 1988) |
| "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia." | ( Immesoete, C; Joos, R; Proot, F; Williame, LM, 1987) |
| "The effects were studied of one week of treatment of rheumatoid arthritis patients with suprofen or ibuprofen on Na+ and K+ excretion, creatinine clearance, urinary enzymes that are markers for tubular damage, and urinary prostaglandins such as PGE2 and 6-keto PGF1 alpha (a stable metabolite of prostacyclin)." | ( Angelini, M; Baldini, L; Barenghi, L; Borsa, M; Carrabba, M; Ceriotti, F; Malandrino, S; Tonon, GC, 1987) |
| "Both drugs were effective in the treatment of rheumatoid arthritis and were well tolerated." | ( Schorn, D, 1985) |
| "MTX appears to be effective in the treatment of active rheumatoid arthritis but requires close monitoring for toxicity." | ( Alarcón, GS; Billingsley, LM; Guttadauria, M; Luggen, ME; Polisson, RP; Samuelson, CO; Weiner, SR; Williams, HJ; Willkens, RF; Yarboro, C, 1985) |
| "Both drugs were effective in the treatment of rheumatoid arthritis and resulted in comparable improvement in efficacy variables." | ( Germain, BF; Meisel, AD, 1985) |
| "To assess the benefit of further gold treatment of rheumatoid arthritis (RA) patients who had already received more than 6 g of this metal, 24 such patients were included in a double-blind trial." | ( Cats, A; Dijkmans, BA; Hermans, J; Van der Leeden, H, 1986) |
| "The use of D-penicillamine in the treatment of rheumatoid arthritis is known to be complicated by the development of various glomerulonephritides." | ( Johnson, K; Rehan, A, 1986) |
| "Cytostatic drugs have been used in the treatment of rheumatoid arthritis but are of limited clinical application due to their severe toxic side-effects." | ( Cunliffe, CJ; Foster, SJ; McCormick, ME, 1983) |
| "The effect of this drug in the treatment of rheumatoid arthritis (RA) was evaluated." | ( Goldstein, G; Mielants, H; Newdeck, E; Power, D; Spiro, T; Verbruggen, G; Veys, EM, 1984) |
| "In untreated rheumatoid arthritis 20% of the patients has a EOG Lp/Dt ratio lower than the lower 5% limit calculated for normal patients." | ( Broekhuyse, RM; Pinckers, A, 1983) |
| "A pilot study evaluated once-daily treatment of rheumatoid arthritis with choline magnesium trisalicylate (CMT) in patients diagnosed as having classical or definite rheumatoid arthritis, with morning stiffness as a major complaint." | ( Boyer, JT; Mann, CC, 1984) |
| "Penicillamine treatment of rheumatoid arthritis was compared with gold and other remittive agents by reviewing the literature and studying the patients in our penicillamine clinic with respect to their previous responses to chrysotherapy." | ( Atkins, CJ; Offer, RC; Ruedy, J; Stein, HB, 1984) |
| "The cytotoxic agents used to treat rheumatoid arthritis, which likely have nonspecific anti-inflammatory actions and have serious long-term side effects, are also briefly reviewed." | ( Anastassiades, TP, 1980) |
| "Our experience with azathioprine in the treatment of rheumatoid arthritis covers ten years, during which 91 rheumatoid patients (66 female and 25 male) received this drug, with a median treatment period of 36 months." | ( Boerbooms, AM; Kruijsen, MW; Speerstra, F; van Beusekom, HJ; van de Putte, LB; Vandenbroucke, JP, 1982) |
| "The effectiveness of fenclofenac in the treatment of rheumatoid arthritis was compared in a crossover double-blind study of 30 patients with that of indometacin over a period of two weeks." | ( Bachmann, F, 1980) |
| "Two studies of its use in treating rheumatoid arthritis are reported here." | ( Camp, AV, 1981) |
| "The place of this new drug in the basic treatment of rheumatoid arthritis requires further study by a double blind test with D-penicillamine, and this is at present in progress." | ( Barbieri, P; Ciompi, ML; Colamussi, V; Mazzoni, MR; Pasero, G; Pellegrini, P, 1980) |
| "She had been treated for rheumatoid arthritis for more than ten years using steroids." | ( Hosaka, S; Iida, Y; Morishita, A; Oyama, T; Tsuchiya, K; Uwabe, K, 1995) |
| "Cyclosporine may be useful in the treatment of rheumatoid arthritis refractory to other immunosuppressive agents, in doses of less than 10 mg/kg/day to minimize its nephrotoxic potential, that is enhanced with prolonged use or concomitant administration of anti-inflammatory drugs." | ( Figueroa, F; Gutiérrez, F; Jacobelli, S; Martínez, ME; Massardo, L; Rivero, S, 1995) |
| "Sulfasalazine is an effective treatment for rheumatoid arthritis (RA), producing improvements in disease parameters similar to those seen with penicillamine, hydroxychloroquine or oral or parenteral gold in comparative clinical trials." | ( Faulds, D; Noble, S; Rains, CP, 1995) |
| "Despite the progress in the treatment of rheumatoid arthritis (RA), many patients continue to suffer from persistent and painful synovitis." | ( Aguilera, S; Donoso, I; Pizzi, T, 1994) |
| "In recent years we have treated 4 rheumatoid arthritis (RA) patients who developed gold-induced enterocolitis, a well-recognized, although rare, complication of chrysotherapy." | ( Abend, Y; Becker, S; Brautbar, C; Cohen, P; Evron, E; Fenakel, G; Geltner, D; Sthoeger, Z, 1995) |
| "Oral glucocorticoids are widely used to treat patients with rheumatoid arthritis, but their effect on joint destruction, as assessed radiologically, is uncertain." | ( Kirwan, JR, 1995) |
| "D-penicillamine, a drug used to treat rheumatoid arthritis, Wilson's disease, and cystinuria, can cause myasthenia gravis." | ( Adelman, HM; Mahan, CS; Wallach, PM; Winters, PR, 1995) |
| "Sulfasalazine is an efficient treatment for rheumatoid arthritis (RA), but its mode of action is not known." | ( Anaya, JM; Bologna, C; Jorgensen, C; Reme, T; Sany, J, 1993) |
| "D-penicillamine has been used in the treatment of rheumatoid arthritis for years." | ( Frey, RA; Keller, F; Michel, BA, 1994) |
| "Sulphasalazine a drug used for the treatment of rheumatoid arthritis (RA) shows a wide range of biological activities all of which might contribute to the beneficial clinical effect seen during treatment of RA." | ( Björk, J; Smedegård, G, 1995) |
| "In the treatment of rheumatoid arthritis an irreplaceable position is held by so-called disease modifying drugs." | ( Trnavský, K, 1995) |
| "The role of corticosteroids in treating rheumatoid arthritis is controversial, but recourse to the available evidence of efficacy should guide patient management decisions." | ( Kirwan, JR; Lim, KK, 1996) |
| "Use of methotrexate to treat rheumatoid arthritis is associated with pulmonary adverse effects in 3% to 5% of cases." | ( Cortet, B; Delcambre, B; Duquesnoy, B; Flipo, RM; Lafitte, JJ; Roux, N; Tonnel, AB, 1996) |
| "We have reviewed the treatment of rheumatoid arthritis (RA) in pertinent selected literature with a focus on methotrexate (MTX)." | ( Kremer, JM, 1996) |
| "They are of value in the treatment of rheumatoid arthritis (RA) and other arthritides with inflammatory characteristics and are frequently used to treat osteoarthritis (OA) when simple analgesics fail to provide relief." | ( Moskowitz, RW, 1996) |
| "No alternative therapy recommended to treat acute rheumatoid arthritis in lieu of cortisone proved to be effective." | ( Hetenyi, G; Karsh, J, 1997) |
| "During the past few years the treatment of rheumatoid arthritis, the most frequent of the rheumatic inflammatory systemic diseases has improved a great deal." | ( Aeschlimann, AG, 1998) |
| "That DMARDs are effective in treating rheumatoid arthritis is beyond question-just how effective they are and what combinations of DMARDs will show improved efficacy will provide data for the next annual review." | ( Brooks, P; Conaghan, PG; Li, E, 1998) |
| "To optimize treatment for rheumatoid arthritis (RA) and to define indications for D-penicillamine and methotrexate therapies on an individual basis by taking into account the levels of rheumatoid factor (RF) isotopes circulating in blood." | ( Derevianko, LI; Sivordova, LE; Zavodovskiĭ, BV; Zborovskaia, IA; Zborovskiĭ, AB, 1999) |
| "Methotrexate is an effective treatment for rheumatoid arthritis and is fairly well tolerated by patients when used appropriately." | ( Wong, BJ, 1993) |
| "Since modern treatment of rheumatoid arthritis (RA) is shifting toward aggressive antirheumatic therapy in an early phase of the disease, diagnostic tests with high specificity are desirable." | ( Breedveld, FC; de Jong, BA; Hazes, JM; Schellekens, GA; van den Hoogen, FH; van Venrooij, WJ; Visser, H, 2000) |
| "Leflunomide will find its place in the treatment of rheumatoid arthritis." | ( Andresen, PN; Hansen, G; Hørslev-Petersen, K, 2000) |
| "In the treatment of rheumatoid arthritis, one therapy that has been identified as having potential benefit, is herbal medicine (phytotherapy)." | ( Little, C; Parsons, T, 2001) |
| "This new concept of immunobiological treatment of rheumatoid arthritis has yielded successful results." | ( Dougados, M; Richard-Miceli, C, 2001) |
| "To study the mechanism of treatment of rheumatoid arthritis with Tripterygium wilfordii Hook." | ( Guo, W; Ma, L; Tao, X, 2001) |
| "Prior to admission, she had been treated for rheumatoid arthritis with methotrexate 7." | ( Beaman, JM; Hackett, LP; Illett, KF; Luxton, G, 2002) |
| "The agent has been developed for the treatment of rheumatoid arthritis, but its multiple immunomodulatory properties may in the future be of interest in the treatment of other rheumatic and immunological diseases." | ( Johnsen, V; Kvien, TK; Rødevand, E, 2001) |
| "Bucillamine is used mainly in treating rheumatoid arthritis (RA)." | ( Fujii, K; Kishimoto, N, 2002) |
| "The use of TNFalpha blockers in the treatment of rheumatoid arthritis and Crohn's disease, with their dramatic immediate effects, comparable with those of the glucocorticoids but without the side effects of the latter, points us in that direction." | ( Neeck, G, 2002) |
| "TNFalpha-antibody treatment for rheumatoid arthritis may compromise the host response to molluscum contagiosum, especially if methotrexate is given additionally." | ( Antoni, C; Cursiefen, C; Dechant, C; Grunke, M; Holbach, LM; Jünemann, A, 2002) |
| "We sought to determine the effects of treating rheumatoid arthritis with antirheumatic drugs on these abnormal lipid levels." | ( Choi, HK; Kim, DK; Kim, MY; Lee, SK; Lee, WK; Park, YB; Song, J, 2002) |
| "It has also been evaluated for the treatment of rheumatoid arthritis, ankylosing spondylitis and acute 'rheumatic' pain." | ( Fleischmann, R; Iqbal, I; Slobodin, G, 2002) |
| "A number of clinical trials for the treatment of rheumatoid arthritis(RA) with infliximab indicated that TNF alpha blockade was effective and well tolerated with the excellent results occurring at 3 and 10 mg/kg in combination with methotrexate." | ( Akahoshi, T; Watabe, H, 2002) |
| "Comparisons are made with the treatment of rheumatoid arthritis." | ( Fraser, AG, 2003) |
| "We report the case of a female patient treated for rheumatoid arthritis, who had gold salt overdose, and in whom acute cholestatic hepatitis occurred three weeks after beginning of therapy." | ( Basset, C; Denis, J; Poupon, J; Vadrot, J; Zafrani, ES, 2003) |
| "Due to these new therapeutic concepts treatment of rheumatoid arthritis with corticoids is experiencing a revival." | ( Kaiser, H, 2003) |
| "(1) Low-dose methotrexate, as used to treat rheumatoid arthritis and psoriasis, can cause cutaneous and buccal ulceration." | ( , 2003) |
| "Methotrexate (MTX), widely used in the treatment of rheumatoid arthritis (RA), inhibits dihydrofolate reductase (DHFR) and folate-dependent enzymes." | ( Hiyama, K; Kohno, N; Kumagai, K; Maeda, H; Oyama, T, 2003) |
| "Precise diagnosis and follow up treatment of rheumatoid arthritis (RA) requires objective quantification, which is still lacking." | ( Bögl, K; Graninger, W; Kainberger, F; Peloschek, P; Smolen, JS; Wick, M, 2003) |
| "It has potential for the treatment of rheumatoid arthritis." | ( , 2003) |
| "Older disease modifying agents for treating rheumatoid arthritis were limited by long-term toxicity." | ( Finesilver, AG, 2003) |
| "Chrysotherapy - the treatment of rheumatoid arthritis (RA) patients with monovalent gold drugs possessing anti-inflammatory and other properties - has been used with some success for more than 70 years; however, the metabolites generated from gold drugs have not been identified positively and the mechanisms of action are not known with certainty." | ( Eisler, R, 2003) |
| "A number of clinical trials for the treatment of rheumatoid arthritis with infliximab indicated that TNF alpha blockade was effective and well tolerated, with excellent results occurring at 3 and 10 mg/kg in combination with methotrexate." | ( Budzyńska, R; Zakliczyńska, H, 2004) |
| "Etanercept is effective in the treatment of rheumatoid arthritis (RA)when used as monotherapy and in combination with methotrexate(MTX)." | ( Genovese, MC; Kremer, JM, 2004) |
| "Anakinra is safe and effective in the treatment of rheumatoid arthritis, both as monotherapy and in combination with other disease-modifying antirheumatic drugs." | ( Cohen, SB, 2004) |
| "Anti-TNFalpha treatment in rheumatoid arthritis results in a decrease in the serum titres of RF and anti-CCP antibodies in patients showing clinical improvement, suggesting that these measurements may be a useful adjunct in assessing treatment efficacy." | ( Alessandri, C; Bombardieri, M; Cinquini, M; Magrini, L; Papa, N; Tincani, A; Valesini, G, 2004) |
| "MTX is widely used for the treatment of rheumatoid arthritis (RA)." | ( Aarden, LA; de Lathouder, S; Dijkmans, BA; Gerards, AH, 2004) |
| "Thus we suggest that for PDT treated rheumatoid arthritis, taking the first 20 min after the injection for outside-the-joint excitation employing HMME maybe a good choice." | ( Dou, XM; Huang, NY; Li, JZ; Yu, CQ; Zhao, HY, 2004) |
| "Modern treatment of rheumatoid arthritis." | ( Surányi, P, 2005) |
| "Leflunomide is a new drug for the treatment of rheumatoid arthritis." | ( Antoine, JC; Camu, W; Coudeyre, E; Gabelle, A; Hillaire-Buys, D, 2005) |
| "Bucillamine (BCL), a treatment for rheumatoid arthritis, occasionally causes proteinuria." | ( Hara, S; Hoshino, J; Katori, H; Sawa, N; Suwabe, T; Tagami, T; Takaichi, K; Takemoto, F; Ubara, Y, 2006) |
| "Therefore, active treatment of rheumatoid arthritis is indispensable." | ( Tłustochowicz, W, 2006) |
| "To determine whether drugs used in the treatment of rheumatoid arthritis (RA) contribute to the increased risk of respiratory infection or influence its outcome." | ( Coulson, E; Coyne, P; Hamilton, J; Heycock, C; Kelly, CA; Saravanan, V, 2007) |
| "Biologicals have revolutionised the treatment of rheumatoid arthritis (RA)." | ( Boyce, SH; Gay, RE; Gay, S; Huber, LC; Ink, BS; Künzler, P; Michel, BA, 2008) |
| "Early aggressive treatment of rheumatoid arthritis is associated with improved disease control, slower radiological progression and improved functional outcomes." | ( Alcorn, N; Capell, H; Dale, J; Madhok, R, 2007) |
| "Gene expression of ML3000 treated and untreated rheumatoid arthritis synovial fibroblasts were measured with Affymetrix gene arrays." | ( Gay, RE; Gay, S; Kurowska-Stolarska, M; Laufer, S; Michel, BA; Neidhart, M; Ospelt, C, 2008) |
| "Methotrexate (MTX), widely used in the treatment of rheumatoid arthritis (RA), inhibits dihydrofolate reductase and folate-dependent enzymes." | ( Drozdzik, M; Herczynska, M; Kurzawski, M; Pawlik, A; Safranow, K, 2007) |
| "There has been a paradigm shift in the treatment of rheumatoid arthritis in recent years." | ( Aggarwal, A; Haroon, N; Misra, R, 2008) |
| "During treatment of rheumatoid arthritis by oral tacrolimus therapy, gastrointestinal symptoms were common, early, and dose-dependent." | ( Akimoto, K; Kawai, S; Kusunoki, Y; Nishio, S; Takagi, K, 2008) |
| "This paper reviews recent approaches to treatment of early rheumatoid arthritis (RA) with disease-modifying antirheumatic drugs (DMARDs)." | ( Sizova, L, 2008) |
| "FMS inhibitors may be useful in treating rheumatoid arthritis and other chronic inflammatory diseases." | ( Chaikin, MA; Chen, Y; Cheng, D; Crysler, CS; DesJarlais, RL; Donatelli, RR; Hu, H; Huang, H; Hutta, DA; Manthey, CL; Parsons, WH; Player, MR; Rinker, JM; Schubert, C; Yurkow, E; Zhou, Z, 2009) |
| "The efficacy of abatacept in the treatment of rheumatoid arthritis (RA) has been shown in several clinical phase II and phase III trials, wherein abatacept was used in monotherapy, either in combination with methotrexate (MTX) after MTX-failure, in combination with MTX after failure of anti-TNF-alpha therapy or in combination with TNF-alpha blockers." | ( Dejaco, C; Duftner, C; Schirmer, M; Wipfler, E, 2009) |
| "In severe untreated rheumatoid arthritis (RA), reductions in high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol and total cholesterol have been noted; this is in line with findings in other pathologies/conditions associated with inflammation or infection, such as sepsis, cancer, trauma or the postoperative period." | ( Choy, E; Sattar, N, 2009) |
| "Clinical squeal of the treatment of rheumatoid arthritis patients with methotrexate (MTX) according to the Japanese government recommended dose of 8 mg/week was evaluated prospectively." | ( Abe, S; Hashiramoto, A; Komai, K; Koyama, K; Murata, M; Nakagawa, N; Saegusa, Y; Sakai, Y; Shiozawa, K; Shiozawa, S; Tanaka, C; Tanaka, Y; Terashima, Y; Tsumiyama, K; Yamane, T; Yoshihara, R, 2009) |
| "(1) First-line disease-modifying treatment for rheumatoid arthritis is based on "slow-acting" antirheumatic agents, generally methotrexate." | ( , 2009) |
| "Leflunomide was licensed for the treatment of rheumatoid arthritis in 1998." | ( Alcorn, N; Madhok, R; Saunders, S, 2009) |
| "Methotrexate is effective in treating rheumatoid arthritis (RA)." | ( Chen, A; Liu, J; Wang, H; Wu, D; Xiang, H, 2012) |
| "Early treatment of rheumatoid arthritis (RA) has been shown to retard the development of joint damage for a period of up to 5 years." | ( Blåfield, H; Hannonen, P; Järvenpää, S; Karjalainen, A; Kautiainen, H; Korpela, M; Laasonen, L; Leirisalo-Repo, M; Möttönen, T; Puolakka, K; Rantalaiho, V, 2010) |
| "The use of glucocorticoids in the treatment of rheumatoid arthritis has been widely employed, but, owing to their systemic side-effects and also their susceptibility to the first pass metabolism, their use is being discouraged." | ( Dhanaraju, MD; Elizabeth, S; Gunasekaran, T, 2011) |
| "Despite improved medical treatment of rheumatoid arthritis, carpal tunnel compression, caput ulnae syndrome and palmar and dorsal tenosynovitis with potential tendon rupture represent urgent surgical indications." | ( Villiger, PM; Vögelin, E, 2011) |
| "The early diagnosis and treatment of rheumatoid arthritis (RA) are important goals for rheumatologists." | ( Haraoui, B; Pope, J, 2011) |
| "Current treatments for rheumatoid arthritis (RA) have long-term side effects such that new treatments are needed that can safely help manage the disease." | ( Dang, H; Kaufman, DL; Tian, J; Yong, J, 2011) |
| "Rituximab is licensed for the treatment of rheumatoid arthritis in combination with methotrexate and in patients who did not respond or cannot tolerate tumour necrosis factor antagonists." | ( Becerra-Fernandez, E; Leandro, MJ, 2011) |
| "The primary goal in the treatment of rheumatoid arthritis (RA) is to maintain good quality of life by preventing joint destruction and avoiding disability." | ( Ichikawa, N; Yamanaka, H, 2012) |
| "The efficacy of mizoribine (MZR) in treatment of rheumatoid arthritis (RA) was retrospectively investigated in terms of drug survival, improvement in Disease Activity Score-28 (DAS28)-C-reactive protein (CRP), and blood MZR concentration obtained 3 h after dosing (MZR-C3)." | ( Akimoto, M; Arishima, Y; Eiraku, N; Izumihara, T; Matsuda, T; Ohkura, S; Ohtsubo, H; Sunahara, N; Yoshitama, T, 2012) |
| "Methotrexate (MTX) has been used to treat rheumatoid arthritis at low doses and leukemia at high doses; however, this drug can produce severe side effects." | ( Anderson, ME; Gu, LC; Majumdar, S; Malefyt, TR; Siahaan, TJ; Xu, CR; Yakovleva, TV, 2012) |
| "Recently, TGP is widely used to treat rheumatoid arthritis in China." | ( Dai, SM; Zhang, W, 2012) |
| "Although various drugs for the treatment of rheumatoid arthritis (RA) have been used in clinics, RA is not completely curable to date." | ( Che, X; Fan, H; Liu, K; Meng, Q; Xu, H; Yang, M; Zhang, Z, 2012) |
| "While medications used to treat rheumatoid arthritis (RA) may affect survival in RA, few studies take into account the propensity for medication use, which may reflect selection bias in treatment allocation in survival models." | ( Dasgupta, A; Fries, JF; Hubert, H; Ward, MM; Wasko, MC, 2013) |
| "This era of early aggressive treatment of rheumatoid arthritis (RA) calls for criteria that allow timely classification of patients at risk of persistent erosive disease." | ( van de Laar, MA; Vonkeman, HE, 2013) |
| "Early, intensive treatment of rheumatoid arthritis (RA) with the combination of (initially high dose) prednisolone, methotrexate and sulfasalazine (COBRA therapy) considerably lowers disease activity and suppresses radiological progression, but is infrequently prescribed in daily practice." | ( Boers, M; den Uyl, D; Dijkmans, B; Kerstens, P; Lems, W; Nurmohamed, M; Raterman, H; ter Wee, M; van Dillen, N; van Schaardenburg, D; Voskuyl, A, 2014) |
| "In the Treatment of Early Rheumatoid Arthritis (TEAR) trial, 755 participants with early, poor-prognosis RA were randomized to receive MTX monotherapy or combination therapy (MTX plus etanercept or MTX plus sulfasalazine plus hydroxychloroquine)." | ( Bridges, SL; Cofield, SS; Curtis, JR; Mikuls, TR; Moreland, LW; O'Dell, JR; Ranganath, VK, 2013) |
| "Various medications are used for the treatment of rheumatoid arthritis (RA)." | ( Masuko, K; Matsui, T; Tohma, S, 2013) |
| "Drug-based treatment of rheumatoid arthritis (RA) has evolved markedly over the past 2 decades." | ( Hakala, M; Jämsen, E; Kauppi, MJ; Lehto, MU; Malmivaara, A; Virta, LJ, 2013) |
| "Methotrexate (MTX) is the anchor treatment for rheumatoid arthritis (RA) and has been very thoroughly studied in many different patient populations, as monotherapy and in combination with various other disease modifying antirheumatic drugs and biologic agents, as they became available." | ( Bata, Y; Yazici, Y, 2013) |
| "Prednisone is a well-established treatment option in rheumatoid arthritis." | ( Henness, S; Yang, LP, 2013) |
| "Tofacitinib was effective in the treatment of active rheumatoid arthritis in patients with an inadequate response or intolerance to at least one DMARDs." | ( Berhan, A, 2013) |
| "To improve treatment for rheumatoid arthritis (RA), rheumatologists have embraced patient-reported outcomes; however, limited data are available on patient perceptions of treatment." | ( Nash, P; Nicholls, D, 2013) |
| "To compare the approved treatment of rheumatoid arthritis using rituximab + methotrexate (RTX + MTX) versus the off-label treatment variants of RTX in monotherapy or RTX in combination with leflunomide (RTX + LEF)." | ( Bussmann, A; Herzer, P; Listing, J; Richter, A; Strangfeld, A; Wilden, E; Zink, A, 2014) |
| "Use of tocilizumab for treating rheumatoid arthritis can become affordable, if costs of its use become lower." | ( Janković, SM; Jovanović, S; Kostić, M; Milenković, MP; Tomović, M, 2014) |
| "Our study showed that treatment of early rheumatoid arthritis with a combination regime of traditional DMARDs is highly effective in controlling disease activity as well as cardiovascular risk." | ( Biswas, M; Chatterjee, S; Ghosh, A; Ghosh, S; Sarkate, P, 2013) |
| "Rituximab (RTX) treatment in rheumatoid arthritis (RA) patients severely hampers humoral response after influenza vaccination as determined by haemagglutination inhibition assay (HI)." | ( Bijl, M; de Haan, A; Horst, G; Land, J; van Assen, S; Westra, J; Wilting, KR, 2014) |
| "Hand exercises are often part of the treatment of hand rheumatoid arthritis; however, it is still unclear whether and what type of exercises is effective in the treatment of this condition." | ( Bergstra, SA; Caljouw, SR; Murgia, A; Te Velde, AF, 2014) |
| "Early diagnosis and treatment of rheumatoid arthritis are associated with improved outcomes but current diagnostic tools such as rheumatoid factor or anti-citrullinated protein antibodies have shown limited sensitivity." | ( Dakna, M; Husi, H; Johnsson, H; Klein, J; McInnes, IB; Mischak, H; Mullen, W; Porter, D; Stalmach, A, 2014) |
| "Clinical efficacy in the treatment of rheumatoid arthritis with anti-CD20 (Rituximab)-mediated B-cell depletion has garnered interest in the mechanisms by which B cells contribute to autoimmunity." | ( Cao, Y; Finnegan, A; Hamel, KM; Olalekan, SA, 2015) |
| "Optimal outcome of treatment in rheumatoid arthritis (RA) is early clinical remission to delay joint damage." | ( Suwannalai, P; Wacharapornin, P, 2014) |
| "Current treatment of rheumatoid arthritis includes systemic administration of glucocorticoids." | ( Boerman, OC; Gerrits, D; Laverman, P; Metselaar, JM; Storm, G; van der Geest, T; van Lent, PL, 2015) |
| "Antimalarials have been used for the treatment of rheumatoid arthritis (RA) for several decades." | ( Cusnir, I; Dobing, S; Jones, N; Russell, A, 2015) |
| "TAC was approved in Japan for the treatment of rheumatoid arthritis (RA) in 2005." | ( Ishida, K; Shiraki, K; Yoshiyasu, T, 2015) |
| "After clinical remission of scabies, treatment of active rheumatoid arthritis with adalimumab was restarted without any complications." | ( Čulo, MI; Gudelj Gračanin, A; Marković, I; Mitrović, J; Morović-Vergles, J; Pukšić, S, 2015) |
| "Methotrexate is the first line of treatment of rheumatoid arthritis." | ( Almeida, CR; Bernardes, GJ; Bismuth, G; Burnet, M; Carmo, AM; Cavaco-Paulo, A; Charvet, C; Freitas, J; Gomes, AC; Lager, F; Le Roux, D; Loureiro, A; Machacek, C; Moreira, A; Nogueira, E; Nogueira, P; Ohradanova-Repic, A; Preto, A; Renault, G; Stockinger, H, 2015) |
| "Methotrexate is in the centre of the treatment of rheumatoid arthritis." | ( Fiehn, C, 2016) |
| "Sulfasalazine (SSZ), a drug used in the treatment of rheumatoid arthritis (RA), inhibits glutamate-cystine transport, and suppressed CD44v-dependent tumor growth and increased sensitivity to cytotoxic drugs in an in vivo study." | ( Kubo, T; Morikawa, A; Morita, T; Nagano, O; Saya, H; Takayama, T, 2016) |
| "Recent advance in treatment of rheumatoid arthritis (RA) has been derived by biological disease-modifying antirheumatic drugs (bDMARDs) targeting cytokines." | ( Sonomoto, K; Tanaka, Y, 2015) |
| "The early diagnosis and treatment of rheumatoid arthritis (RA) is important to reduce joint destruction." | ( Funayama, T; Hara, I; Onishi, S; Ozeki, E; Sakane, M; Tsukanishi, T; Yamazaki, M, 2016) |
| "Developing inhibitors of any kinase to treat of rheumatoid arthritis has proved problematic with regard to both efficacy and selectivity." | ( Norman, P, 2016) |
| "A 75-year-old female with untreated rheumatoid arthritis presented with two weeks of behavioral changes and cognitive decline." | ( Killory, BD; Nouh, AM; Ollenschleger, MD; Song, X; Stretz, C, 2016) |
| "The biologics have revolutionized the treatment of rheumatoid arthritis (RA)." | ( Yamaoka, K, 2016) |
| "Proper diagnosis and treatment of rheumatoid arthritis are extremely important to optimize treatment outcomes." | ( Al Faruque, H; Chang, Y; Hong, J; Kang, YM; Kim, EH; Lee, J; Lee, JJ; Park, JW; Sung, S, 2016) |
| "Biologics have revolutionized the treatment of rheumatoid arthritis (RA)." | ( Yamaoka, K, 2016) |
| "To evaluate subcutaneous SBI-087 to treat rheumatoid arthritis (RA)." | ( Aelion, J; Bhattacharya, I; Damjanov, N; Diehl, A; Gourley, I; Greenwald, M; Menon, S; Peeva, E; Tlustochowicz, M, 2016) |
| "They used it successfully in treating rheumatoid arthritis (RA)." | ( Malaviya, AN, 2016) |
| "Since prednisolone is used to treat rheumatoid arthritis at a dose ≤10 mg/d, the patients were divided based on the prednisolone dose into the groups treated at >10 and ≤10 mg/d, and the onset time was investigated in each group." | ( Hara, A; Kizu, J; Matsumoto, K; Yokoyama, Y, 2017) |
| "It is established that treatment for rheumatoid arthritis can exacerbate latent viral issues, but this has not specifically been reported for vestibular neuritis." | ( Roberts, RA, 2018) |
| "Corticosteroids (CSs), used to treat rheumatoid arthritis (RA), confer a risk of adverse events (AEs)." | ( Kishimoto, M; Ohde, S; Okada, M; Suda, M; Tsuda, T, 2018) |
| "Optimal targeted treatment in rheumatoid arthritis requires early identification of failure to respond." | ( Chapman, D; DeMasi, R; Fallon, L; Keystone, E; Lee, EB; van Vollenhoven, RF; Wilkinson, B; Zwillich, SH, 2019) |
| "While highly efficacious in treating rheumatoid arthritis (RA), the approved Janus kinase (JAK) inhibitor, Tofacitinib (Tofa, CP-690 550), has dose-dependent toxicities that limit its clinical application." | ( Galdamez, J; Goldring, SR; Lele, SM; Liu, Y; Mikuls, TR; Purdue, PE; Soni, DM; Wang, D; Wang, X; Wei, X; Wu, J; Zhao, G, 2018) |
| "Medication-based strategies to treat rheumatoid arthritis are crucial in terms of outcome." | ( Alten, R; Baerwald, C; Behrens, F; Braun, J; Burkhardt, H; Burmester, G; Detert, J; Fiehn, C; Frerix, M; Gaubitz, M; Gause, A; Gromnica-Ihle, E; Holle, J; Iking-Konert, C; Kellner, H; Krause, A; Krüger, K; Kuipers, J; Leipe, J; Lorenz, HM; Müller-Ladner, U; Nothacker, M; Nüsslein, H; Rubbert-Roth, A; Schneider, M; Schulze-Koops, H; Seitz, S; Sitter, H; Specker, C; Tony, HP; Wassenberg, S; Weseloh, C; Wollenhaupt, J, 2018) |
| "Methotrexate has been used in treatment of rheumatoid arthritis (RA) since the 1980s and to this day is often the first line medication for RA treatment." | ( Cronstein, B; Friedman, B, 2019) |
| "The use of methotrexate (MTX) to treat rheumatoid arthritis (RA) is increasing." | ( Kikuchi, N; Koda, M; Kono, M; Murakami, K; Shimizu, T; Tanaka, H; Uesugi, M; Yamazaki, M, 2018) |
| "Current guidelines on the treatment of rheumatoid arthritis (RA) recommend early therapy targeting the achievement of low disease activity (LDA) or clinical remission." | ( Abud-Mendoza, C; Borlenghi, CE; De Angelo Andrade, M; Mendez-Patarroyo, P; Pedersen, R; Vlahos, B; Zerbini, CAF, 2018) |
| "She had also been treated for rheumatoid arthritis with prednisolone, methotrexate, and tocilizumab (interleukin-6 receptor inhibitor)." | ( Fujii, Y; Goto, Y; Imura, H; Matono, T; Nagano, S; Tobino, K; Yaguchi, T; Yamate, R, 2019) |
| "Clinical remission is the treatment target in rheumatoid arthritis (RA)." | ( Cai, YM; Gan, YZ; He, J; Li, J; Li, R; Li, SG; Li, ZG; Liao, H; Liu, JJ; Liu, X; Shi, LJ; Sun, XL; Xu, J; Ye, H; Zhang, RJ; Zhao, JX, 2019) |
| "We enrolled six treatment-naive rheumatoid arthritis (RA) patients whose blood samples were collected for phenotypic and molecular studies along with 12-week iguratimod monotherapy." | ( Bao, C; Du, F; Fu, Q; Guo, Q; Hao, P; Liu, M; Liu, Y; Tang, L; Yan, Q; Ye, Y; Zhang, X, 2019) |
| "Oral treatment of rheumatoid arthritis (RA) with the immunomodulator, leflunomide (LEF), is associated with systemic side effects namely immunosuppression and hepatotoxicity." | ( Boraie, N; Helmy, MW; Nafee, N; Zewail, M, 2019) |
| "Patients with long-term, treated, rheumatoid arthritis (RA) show abnormalities in their circulating CD4+ T-lymphocytes, but whether this occurs in recently diagnosed naïve patients to disease-modifying drugs (DMARDs) is under discussion." | ( Albarrán, F; Álvarez-Mon, M; Bohórquez, C; Chara, L; Díaz, D; Gómez Lahoz, AM; Monserrat, J; Movasat, A; Pérez, A; Ruíz, L; Sánchez, AI; Sanz, I, 2019) |
| "We describe the Treatment for Rheumatoid Arthritis and Interstitial Lung Disease 1 (TRAIL1) trial, a multicenter randomized, double-blind, placebo-controlled, phase 2 study of the safety, tolerability and efficacy of pirfenidone in patients with RA-ILD." | ( Chambers, DC; Danoff, SK; Dellaripa, PF; DiFranco, D; Goldberg, HJ; Haynes-Harp, S; Hurwitz, S; Kolb, M; Peters, EB; Rosas, IO; Solomon, JJ; Spino, C; Woodhead, F, 2019) |
| "A total of 170 patients who had been treated for rheumatoid arthritis at our hospital from August 2016 and June 2018, were enrolled as research objects." | ( Ji, H; Sun, Q; Tang, Z, 2019) |
| "Clinical trials of treating rheumatoid arthritis with Tripterygium Glycosides Tablets published by Meta-analysis were retrieved from EMbase,PubMed,Clinical Trials,Web of Science,Cochrane Library,CNKI,Wanfang,VIP,CBM and Chi CTR,and comprehensively analyzed." | ( Gao, Y; Han, XC; Wang, HL; Wang, HZ; Yang, YZ; Zhu, GZ, 2019) |
| "Despite significant progress in treatment of rheumatoid arthritis (RA), a considerable part of patients remains resistant to the current therapy, apparently for the reasons of undefined mechanisms of its pathogenesis." | ( Khomenko, V; Stanislavchuk, M; Zaichko, K; Zaichko, N, 2020) |
| "RESULTS Treatment of rheumatoid arthritis with RT-Pt(II) significantly reduced the levels of IL‑1ß, IL-6, IL-8, MMP-1, and MMP-13 in synovial fluid of mice in a dose-dependent manner." | ( Cao, L; Cui, L; Cui, Z; Lin, Y; Liu, Y, 2020) |
| "Glucocorticoids (GCs) show powerful treatment effect on rheumatoid arthritis (RA)." | ( Cai, L; Chen, X; Feng, Y; Li, C; Li, H; Mei, Z; Wang, Y; Yan, F; Zhong, Z, 2020) |
| "Up to 3% of methotrexate (MTX)-treated rheumatoid arthritis (RA) patients might develop liver fibrosis or cirrhosis, requiring effective screening algorithms." | ( Ayonrinde, OT; Keen, HI; Olsson-White, DA; Olynyk, JK; Paramalingam, S, 2022) |
| "To identify the optimal treatment for rheumatoid arthritis (RA) after the regression of lymphoproliferative disorders (LPDs)." | ( Fujii, T; Harigai, M; Kaneko, Y; Kuramoto, N; Nakano, K; Saito, K; Saito, R; Saito, S; Sasaki, S; Sugimoto, N; Suzuki, Y; Takada, H; Tanaka, M; Tanaka, Y, 2022) |
| "Even though new drugs for the treatment of rheumatoid arthritis (RA) have been developed, methotrexate (MTX) remains a commonly used drug for RA management." | ( Abdulah, R; Destiani, DP; Dewi, S; Naja, S; Rahmadi, AR; Sulaiman, SAS, 2021) |
| "Patients aged 18 years and older with treatment naive rheumatoid arthritis, symptom duration less than 24 months, moderate to severe disease activity, and rheumatoid factor or anti-citrullinated protein antibody positivity, or increased C reactive protein." | ( Baecklund, E; Bakland, G; Brodin, E; Cagnotto, G; Ellingsen, T; Faustini, F; Grondal, G; Grøn, KL; Gudbjornsson, B; Haavardsholm, EA; Heiberg, MS; Hendricks, O; Hetland, ML; Hultgård Ekwall, AK; Husmark, T; Hyldstrup, LH; Hørslev-Petersen, K; Just, SA; Kapetanovic, M; Krabbe, S; Lampa, J; Larsson, P; Laurberg, TB; Lend, K; Lindqvist, J; Ljoså, MA; Lorenzen, T; Nordström, D; Nurmohamed, M; Olsen, IC; Olsson, ÅR; Rizk, M; Rudin, A; Söderbergh, A; Sokka-Isler, T; Stevens, DJ; Tuompo, R; Twisk, J; Uhlig, T; Uhrenholt, L; van Vollenhoven, R; Vedder, D; Østergaard, M, 2020) |
| "Cortisone was introduced in the treatment of rheumatoid arthritis (RA) in 1948 by Hench and colleagues at the Mayo Clinic which resulted in dramatic improvement of inflammation, function and sense of well-being." | ( Conn, DL, 2021) |
| "Tocilizumab is widely used in treating rheumatoid arthritis and has the potential to reduce the mortality rate among severe COVID-19 patients." | ( Huang, KY; Kuo, MH; Lai, NS; Lee, CH; Lu, MC; Tseng, CW; Tseng, KC; Tung, CH, 2021) |
| "Methotrexate, which had been used to treat her rheumatoid arthritis, could subsequently be administered in a reduced dose." | ( Horimoto, Y; Murakami, F; Saito, M; Shimizu, H; Tada, K; Tamura, N; Yamaji, K, 2021) |
| "In the treatment of rheumatoid arthritis (RA), Janus kinase inhibitors (jakinibs) represent an emerging class of targeted therapies in addition to biologics." | ( Kavanaugh, A; McInnes, IB; Tanaka, Y; Wicklund, J, 2022) |
| "Thus, MTX-PEC demonstrated potential to treat rheumatoid arthritis, with the possibility of decreasing the systemic exposure to the drug." | ( Agostini, SBN; Bassi da Silva, J; Bruschi, ML; Carvalho, FC; de Oliveira, MK; Dos Santos, RS; Elisei, LS; Freitas, JTJ; Galdino, G; Giusto, LADR; Lino, MES; Malta, IHS; Moraes, TR; Nogueira, DA; Novaes, RD; Pereira, GR; Rodrigues, RF; Santos, AMD, 2021) |
| "Tofacitinib tablet is approved for the treatment of rheumatoid arthritis (RA)." | ( Li, Y; Sun, Y; Wei, S; Zhang, L; Zong, S, 2021) |
| "One of the treatments for rheumatoid arthritis (RA) was methotrexate which a disease modifying antirheumatic drug therapy." | ( Achmad, A; Putra Suryana, BP; Rahmayanti, TY, 2021) |
| "Sinomenine (SIN) is a clinical drug for treating rheumatoid arthritis (RA) in China." | ( Dong, Y; Du, Q; Ke, J; Lai, H; Liu, J; Liu, L; Lv, Y; Peng, C; Wang, P; Yi, L; Zhi, Y; Zhou, H, 2021) |
| "Methotrexate (MTX) is the first line treatment of rheumatoid arthritis (RA), and methylation changes in bulk T cells have been reported after treatment with MTX." | ( Andreassen, BK; Evenrød, IM; Flåm, ST; Franke, A; Franzenburg, S; Gervin, K; Guderud, K; Lie, BA; Mjaavatten, MD; Mæhlen, MT; Norli, ES; Rayner, S; Sunde, LH, 2021) |
| "a current standards-of-care for treating flares in rheumatoid arthritis patients)." | ( Bijlsma, JWJ; Bos, R; Kothekar, M; Lammers, T; Metselaar, JM; Middelink, LM; Raut, A; van Laar, JM; Vonkeman, HE; Westhovens, R; Wortel, CH; Yao, SL, 2022) |
| "Abatacept (CTLA4-Ig) is used for the treatment of Rheumatoid arthritis." | ( Kadu, P; Kale, P; Kulkarni, D; Naik, J; Pandya, A, 2022) |
| "Methotrexate (MTX) is the first-line treatment for rheumatoid arthritis (RA)." | ( Cao, Z; Huang, Q; Li, C; Liu, R; Liu, Y; Lu, A; Lu, C; Song, Y; Xue, Z; Yu, L; Zhang, Z; Zhu, D, 2022) |
| "Current treatment for Rheumatoid arthritis (RA) utilizes Disease-modifying antirheumatic drugs, non-steroidal anti-inflammatory drugs or its combination, to decrease joint inflammation." | ( Babasahib, SK; Born, RW; Raghavendra, NM, 2022) |
| "Hydroxychloroquine, when used to treat patients with rheumatoid arthritis or systemic lupus erythematosus, has been found to reduce cardiovascular disease (CVD)." | ( Porter, M; Weidman-Evans, E, 2022) |
| "Rituximab is used for the treatment of active rheumatoid arthritis." | ( Avgoustidis, N; Bertsias, A; Bertsias, G; Flouri, I; Kalogiannaki, E; Kougkas, N; Papalopoulos, I; Repa, A; Sidiropoulos, P, 2022) |
| "Whereas in the treatment of rheumatoid arthritis much evidence exists on the effects of current pharmacologic treatment on clinical outcomes, little is known about the effects on patient-reported outcomes." | ( de Jong, PHP; Hazes, JMW; Kok, MR; Kuijper, TM; Lopes-Barreto, D; Luurssen-Masurel, N; van den Dikkenberg, M; Weel-Koenders, AEAM, 2023) |
| "It is widely used for the treatment of rheumatoid arthritis in clinic." | ( Dai, Y; Huang, D; Lin, L; Lin, W; Shao, S; Wang, Y; Xia, Y, 2022) |
| "Sulfasalazine has been widely used in treatment of rheumatoid arthritis and spondyloarthritis." | ( David, R; Jayachandran, M; Koshy, V; Marwaha, V; Mithun, CB; Nair, AS; Padmanabhan, DS; Palatty, PL; Santhakumari, V; Singh, SK; Singhal, A; Suman, SK; Surendran, S; Tiwari, A; Yadav, P, 2022) |
| "New evidence for the treatment of rheumatoid arthritis (RA) has emerged during the last year." | ( Adinolfi, A; Bortoluzzi, A; Filippou, G; Garaffoni, C; Giollo, A; Sakellariou, G; Scirè, CA; Silvagni, E; Sirotti, S; Ughi, N, 2022) |
| "Methotrexate, the cornerstone treatment of rheumatoid arthritis, initiated at the pre-arthritis stage of symptoms and subclinical inflammation, did not prevent the development of clinical arthritis, but modified the disease course as shown by sustained improvement in MRI-detected inflammation, related symptoms, and impairments compared with placebo." | ( Allaart, CF; Boer, AC; Böhringer, S; Burgers, LE; Dakkak, YJ; de Jong, PHP; de Witt-Luth, ME; Huizinga, TWJ; Kok, MR; Krijbolder, DI; Molenaar, ETH; Niemantsverdriet, E; Park, YJ; van der Helm-van Mil, AHM; van Dijk, BT; Verstappen, M; Visser, K, 2022) |
| "Gold salts have been used to treat rheumatoid arthritis (RA) since the 1940s, and, with advances in nanotechnology, the use of nanogold provides multiple options for anti-inflammatory therapies." | ( Carrasco-Hernández, AR; Castellanos-Ponce, I; Duarte-Moller, JA; Esparza-Ponce, HE; Espino-Solís, GP; González-Chávez, SA; López-Loeza, SM; Neri-Flores, MÁ; Pacheco-Tena, C; Ruvalcaba-Ontiveros, RI; Vázquez-Olvera, G, 2022) |
| "Filgotinib has been approved for the treatment of rheumatoid arthritis (RA) in adults who respond inadequately to disease-modifying antirheumatic drugs (DMARDs) in Europe and Japan." | ( Chu, T; Liu, B; Liu, Z; Lu, L; Ma, D; Pan, L; Ren, J; Wang, Y; Yu, L, 2022) |
| "The most used drug for the treatment of rheumatoid arthritis (RA) remains methotrexate (MTX)." | ( Chang, JS; Chang, MJ; Cheng, T; Li, XF; Liu, GY; Qiao, J; Song, S; Zhang, JQ; Zhang, SX; Zhao, R, 2023) |
| "Leflunomide is a commonly used treatment for rheumatoid arthritis." | ( Aicha, BT; Hana, S; Ines, M; Issam, S; Kawther, BA; Leila, A; Leila, M; Lobna, BA; Mouna, BS; Olfa, S; Rawdha, T; Selma, B; Takoua, BB, 2023) |
| "bulbifera in the treatment of rheumatoid arthritis, which laid a theoretical and experimental foundation for further development and application of the medicinal plant." | ( Chen, SY; Chen, Y; Gong, ZP; Huang, Y; Lan, YY; Li, YT; Tang, J; Wang, YL; Wu, D; Zhang, Q; Zheng, L, 2022) |
| "With the in-depth research on treatment drugs of rheumatoid arthritis (RA), a variety of disease modifying anti-rheumatic drugs (DMARDs) have been approved for the treatment of RA." | ( Dai, LY; Zhao, JX, 2022) |
| "Baricitinib (BARI) is approved for the treatment of rheumatoid arthritis (RA) after failure of conventional synthetic and biologic disease modifying anti-rheumatic drugs (cs/bDMARDs) in combination with methotrexate (MTX) or as monotherapy." | ( Bayat, S; Bohr, D; Hartmann, F; Kleyer, A; Knitza, J; Krönke, G; Schett, G; Simon, D; Tascilar, K, 2022) |
| "Baricitinib (BARI) is approved for the treatment of rheumatoid arthritis (RA) after failure of conventional synthetic and biologic disease modifying anti-rheumatic drugs (cs/bDMARDs) in combination with methotrexate (MTX) or as monotherapy." | ( Bayat, S; Bohr, D; Hartmann, F; Kleyer, A; Knitza, J; Krönke, G; Schett, G; Simon, D; Tascilar, K, 2022) |
| "Baricitinib (BARI) is approved for the treatment of rheumatoid arthritis (RA) after failure of conventional synthetic and biologic disease modifying anti-rheumatic drugs (cs/bDMARDs) in combination with methotrexate (MTX) or as monotherapy." | ( Bayat, S; Bohr, D; Hartmann, F; Kleyer, A; Knitza, J; Krönke, G; Schett, G; Simon, D; Tascilar, K, 2022) |
| "Methotrexate (MTX) is a first-line treatment for rheumatoid arthritis (RA), but its clinical use is greatly limited by the adverse effects and poor patient compliance caused by traditional oral administration or injection." | ( Ma, Z; Tao, X; Wang, Q; Yang, J; Zhao, W; Zheng, L, 2023) |
| "Glucocorticoids are used in the treatment of rheumatoid arthritis since many decades." | ( van der Goes, MC, 2022) |
| "Recently, transdermal treatment of rheumatoid arthritis (RA) has received increasing attention due to the advantages of improving patient compliance and avoiding gastrointestinal side effects." | ( Li, Y; Ma, T; Wang, Q; Yang, J; Zhang, Y; Zhao, W; Zheng, L, 2023) |
| "Abatacept (Orencia) is a drug used to treat patients with rheumatoid arthritis." | ( Mohamed Ahamada, M; Wu, X, 2023) |
| "To compare the features of difficult-to-treat rheumatoid arthritis (D2TRA) patients using two different definitions according to the previous failure of targeted therapies." | ( Allanore, Y; Avouac, J; Combier, A; Hecquet, S; Miceli-Richard, C; Molto, A; Pons, M; Steelandt, A; Wendling, D, 2023) |
| "They are widely used in China to treat rheumatoid arthritis (RA), but proof of their use as an evidence-based medicine is little." | ( Fang, J; Hu, J; Huang, Z; Li, W; Liu, C; Liu, M; Lv, L; Ma, Y; Wang, H; Wang, Y; Zheng, X; Zhu, H; Zhu, Z, 2023) |
| "As significant advances in the field of treatment for rheumatoid arthritis (RA), there is a great need to identify the healthcare outcomes such as treatment satisfaction and health-related quality of life (HRQoL) of patients with various treatment options." | ( Choe, JY; Jeon, JY; Kim, SK; Lee, SH; Sun, J; Yoo, HJ, 2023) |
| "However, its potential mechanism in the treatment of rheumatoid arthritis (RA) remains unknown." | ( Bao, TR; Gao, XX; He, XL; Jia, JM; Sun, XD; Wang, AH; Wang, Y; Yan, H; Yang, YC; Zhao, L; Zhu, SY, 2023) |
| "A 56-year-old woman was treated for rheumatoid arthritis for 17 years with methotrexate (MTX)." | ( Kato, H; Kohsaka, H; Misumi, K; Suzuki, M, 2023) |
| "The optimal first-line treatment in early rheumatoid arthritis (RA) is debated." | ( Aga, AB; Back, J; Bakland, G; Bay Laurbjerg, T; Brodin, E; Bøyesen, P; Faustini, F; Giovanni, C; Gjertsson, I; Glinatsi, D; Grenholm, E; Grondal, G; Gudbjornsson, B; Haavardsholm, EA; Heiberg, MS; Hendricks, O; Hetland, ML; Hørslev-Petersen, K; Just, SA; Kapetanovic, MC; Kastbom, A; Krabbe, S; Lampa, J; Larsson, P; Lend, K; Lindegaard, H; Lindqvist, J; Ljoså, MK; Lorenzen, T; Nordström, DC; Nurmohamed, MT; Olsen, IC; Parmanne, P; Rannio, T; Rizk, M; Rudin, A; Söderbergh, A; Sokka, T; Stevens, DJ; Uhlig, T; Uhrenholt, L; van Vollenhoven, RF; Vedder, D; Ørnbjerg, LM; Østergaard, M, 2023) |
| "In the clinical treatment of rheumatoid arthritis, we should focus on improving the blood lipid indexes such as TC and HDL-C, and explore more targeted individualized administration, so as to achieve better and faster treatment effect in patients with rheumatoid arthritis." | ( Chen, K; Huang, X; Wang, Y; Xie, H; Yao, G; Zhu, Y, 2023) |
| "Methotrexate is used in treatment of rheumatoid arthritis." | ( Jingzhou, Z; Xin, KQ; Xiong, Z, 2023) |